Vectored TNF-alpha antagonists for ophthalmic indications
Patent Information
- Application Number
- JP2023526231
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-29
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for non-infectious uveitis, such as biologic agents, require frequent injections and can be burdensome for patients, and there is a need for more effective and sustained delivery methods to reduce treatment frequency and systemic toxicity.
A gene therapy approach using recombinant adeno-associated virus (rAAV) vectors to deliver post-translationally modified anti-TNFα Fc fusion proteins, such as etanercept and EYS606, to the eye or liver, creating a depot for sustained expression and reducing the need for repeated injections.
This method provides sustained therapeutic levels of anti-TNFα Fc fusion proteins, reducing treatment frequency and minimizing systemic exposure, thereby improving patient convenience and safety.
Abstract
Description
[Technical Field]
[0001] 1. Preface This document describes compositions and methods for delivering a fully human post-translationally modified (HuP™) therapeutic tumor necrosis factor receptor (TNFR) fusion protein that binds to tumor necrosis factor alpha (TNF-α) to human subjects diagnosed with non-infectious uveitis. [Background technology]
[0002] 2.Background technology Therapeutic anti-TNFα Fc fusion proteins have been shown to be effective in treating several diseases and conditions. However, because these drugs are only effective for a short period, they often require repeated injections over a long period, which places a considerable treatment burden on patients.
[0003] Uveitis encompasses a heterogeneous group of diseases characterized by inflammation of the uvea. Generally, uveitis can be classified, depending on the etiology of the inflammation, as infectious or non-infectious (autoimmune), potentially related to or unrelated to systemic disease. In addition, uveitis can be anatomically classified as anterior, intermediate, posterior, or panuveitis, and may have an acute, chronic, or recurrent course. Clinical symptoms are variable and may include blurred vision, photophobia, eye pain, and significant visual impairment (Valenzuela et al., Front Pharmacol. 2020;11:655).
[0004] Non-infectious uveitis is a serious, vision-threatening intraocular inflammatory condition characterized by inflammation of the uvea (iris, ciliary body, and choroid). Thought to arise from an immune-mediated response to ocular antigens, non-infectious uveitis is a leading cause of irreversible blindness in the working-age population in developed countries. The goal of uveitis treatment is to control inflammation, prevent recurrence, preserve vision, and minimize the adverse effects of medications. Currently, standard treatment for non-infectious uveitis includes the administration of corticosteroids as a first-line agent, although more aggressive therapy may be necessary in some cases. This includes synthetic immunosuppressants such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurin inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In patients who are intolerant or refractory to corticosteroids and conventional immunosuppressive therapies, biological agents have emerged as effective therapies for uveitis in children and adults, based on their targeting of relevant immunological pathways involved in disease development. Current immunomodulatory therapies include mAbs such as infliximab, adalimumab, golimumab, and certolizumab-pegol, or TNFα inhibition achieved by TNF receptor fusion proteins, etanercept. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. Adalimumab is approved for the treatment of non-infectious uveitis with bi-weekly subcutaneous administration. Other biological agents are recommended when conventional immunosuppressive therapy and / or anti-TNF-α therapy fail.
[0005] EYS606 encodes a recombinant fusion protein that ligates the TNFα p55 receptor 1 (TNFR1) to the Fc portion of an IgG1 immunoglobulin molecule. EYS606 is currently being investigated as a nonviral gene therapy for the treatment of non-infectious posterior, intermediate, or panuveitis. EYS606 is administered by electrotransfer into the patient's ciliary muscle.
[0006] Etanercept is a dimeric fusion protein consisting of two extracellular domains of the human p75 TNFα receptor (TNFR2) fused to the Fc portion of the IgG1 immunoglobulin molecule (TNFR:Fc), and can be used to treat several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. Etanercept is administered subcutaneously at a dose of 50 mg once weekly or 25 mg twice weekly (Valenzuela et al., Front Pharmacol. 2020;11:655).
[0007] More effective treatments are needed to reduce the treatment burden on patients with non-infectious uveitis. Intravitreal drug delivery is a promising mode of drug administration in uveitis patients because it delivers a large amount of drug to target tissue and eliminates the risk of systemic toxicity. Reducing or eliminating the need for regular ocular administration would reduce the burden on patients and improve therapy. [Overview of the project]
[0008] 3. Outline of the Invention Bioinhibitors delivered by gene therapy have several advantages over injected or infused therapeutic bioinhibitors, as they dissipate over time, resulting in peak and trough levels. The sustained expression of the bioinhibitor from the transgene product allows for a more consistent level of the bioinhibitor to be present at the site of action, as opposed to repeated injections, and requires fewer injections, making it less risky and more convenient for the patient. Furthermore, bioinhibitors expressed from transgenes are post-modified in a different manner than those directly injected, due to the different microenvironments present during and after translation. While not constrained by any particular theory, this results in bioinhibitors with different diffusion, bioactivity, distribution, affinity, pharmacokinetic, and immunogenic properties, so that antibodies delivered to the site of action are "better" than directly injected biological agents. Systemic administration, such as expression from a hepatic depot, or, in addition, local delivery of the therapeutic agent to ocular tissue, can reduce the subject's exposure to the therapeutic agent and lower the risk of potential adverse effects. Accordingly, compositions and methods for anti-TNFα gene therapy, particularly recombinant AAV gene therapy, that deliver therapeutic efficacy or prophylactic levels of biological inhibitors in the eye within 20, 30, 40, 50, 60, or 90 days of administration of an rAAV composition designed to target the eye and generate a depot of transgenes for the expression of anti-TNFα Fc fusion proteins (TNFR:Fc), particularly etanercept (TNFR2:Fc) and EYS606 (TNFR1:Fc).
[0009] This invention describes compositions and methods for systemic delivery of anti-TNFα Fc fusion proteins to patients (human subjects) diagnosed with non-infectious uveitis or other conditions indicated for treatment with therapeutic anti-TNFα Fc fusion proteins. Delivery can be advantageously achieved by administering, for example, a viral vector or other DNA expression construct encoding a therapeutic anti-TNFα Fc fusion protein to a subject diagnosed with a condition indicated for treatment with a therapeutic anti-TNFα Fc fusion protein via gene therapy, thereby creating a permanent depot in the patient's eye, or in an alternative embodiment, in the liver and / or muscle, to continuously supply the HuPTM anti-TNFα Fc fusion protein, e.g., a human glycosylated transgene product, to appropriate ocular tissue (including circulatoryly) in the subject where the anti-TNFα Fc fusion protein exerts its therapeutic or prophylactic effect.
[0010] The recombinant vector used to deliver the transgene comprises a non-replicating recombinant adeno-associated virus vector ("rAAV"). In embodiments, the AAV type has ocular tropism, e.g., AAV8 subtype, AAV3B subtype, AAV2.7m8, or AAVrh73 subtype of AAV. However, other viral vectors may be used, including but not limited to lentiviral vectors; vaccinia virus vectors, or nonviral expression vectors referred to as "naked DNA" constructs. Transgene expression may be controlled by constitutive or tissue-specific expression regulatory elements, particularly ocular tissue-specific regulatory elements, e.g., one or more elements in Table 1 or alternatively in Table 1a. The construct may also include signal or leader peptides that direct the secretion of the expressed anti-TNFα Fc fusion protein, e.g., peptides in Table 2, or Table 3 or 4.
[0011] In certain embodiments, the HuPTM anti-TNFα Fc fusion protein encoded by the transgene may include, but is not limited to, a TNFR:Fc fusion protein that binds to TNFα, particularly etanercept (or any of its derivative formulations) or EYS606; see, for example, Figures 2A and 2B.
[0012] The gene therapy construct for therapeutic anti-TNFα Fc fusion protein is designed so that a soluble TNFR (TNFR1 or TNFR2) fused to the Fc portion is expressed as a dimeric fusion protein (SEQ ID NOs: 10 and 12).
[0013] In addition, anti-TNFα Fc fusion proteins expressed in vivo from transgenes are unlikely to contain degradation products associated with biological agents produced by recombinant technologies, such as protein aggregation and protein oxidation. Aggregation is a problem associated with protein production and storage resulting from high protein concentrations, surface interactions with manufacturing equipment and containers, and purification in certain buffer systems. These conditions that promote aggregation are not present in transgene expression in gene therapy. Oxidation, such as methionine, tryptophan, and histidine oxidation, is also associated with protein production and storage and is caused by stressful cell culture conditions, metal and air contact, and impurities in buffers and excipients. Proteins expressed in vivo from transgenes may also be oxidized under stressful conditions. However, humans and many other organisms have antioxidant defense systems that not only reduce oxidative stress but can also repair and / or reverse oxidation. Therefore, proteins produced in vivo are unlikely to be in an oxidized form. Both aggregation and oxidation can affect potency, pharmacokinetics (clearance), and immunogenicity.
[0014] The production of the HuPTM anti-TNFα Fc fusion protein in the eye of human subjects should result in a "bio-better" molecule for the treatment of diseases achieved through gene therapy. This should be achieved by, for example, administering a viral vector encoding the HuPTM anti-TNFα fusion protein, or another DNA expression construct, to patients (human subjects) diagnosed with the disease indication for the Fc fusion protein, thereby creating a permanent depot in the subject that continuously supplies the human glycosylated sulfated transgene product produced by the transduced cells of the subject. The cDNA construct of the HuPTM anti-TNFα Fc fusion protein should contain signal peptides to ensure proper co-translation and post-translational processing (glycosylation and protein sulfated protein) by transduced human cells.
[0015] As an alternative or additional treatment to gene therapy, the HuPTM anti-TNFα Fc fusion protein can be produced in human cell lines by recombinant DNA technology, and the glycoprotein can be administered to patients.
[0016] Combination therapy involving systemic delivery of HuPTM anti-TNFα fusion protein to patients in conjunction with the administration of other available therapies is included in the methods provided herein. Additional therapies may be administered before, concurrently with, or after gene therapy. Such additional therapies may include, but are not limited to, combination therapy with therapeutic anti-TNFα Fc fusion protein or anti-TNFα mAb.
[0017] Methods for producing viral vectors, particularly AAV-based viral vectors, are also provided. In certain embodiments, a method for producing recombinant AAV is provided, comprising: culturing host cells containing an artificial genome containing an artificial genome with sufficient adenovirus helper function to enable replication and packaging of the artificial genome by the AAV capsid protein; and recovering recombinant AAV from the cell culture that capsids the artificial genome.
[0018] A composition is provided comprising an rAAV vector comprising a photoreceptor-specific promoter or other suitable promoter (including the CAG promoter, Best1 / GRK promoter (or other promoters provided in Table 1 or Table 1a)) and an optimized expression cassette containing a codon-optimized and CpG-depleted transgene expressing a transgene, such as a transgene expressing a soluble TNFR (TNFR1 or TNFR2) and Fc domain (including hinge, CH2 and CH3 domains) of an anti-TNFα therapeutic Fc fusion protein (including etanercept and EYS606). Methods of administration and preparation are also provided. In particular, compositions and methods comprising rAAV including construct CAG.etanercept or U1a.Vh4i.etanercept.scAAV are provided (see Table 7).
[0019] Pharmaceutical compositions suitable for administration to human subjects include a suspension of recombinant vectors in a formulation buffer containing a physiologically compatible aqueous buffer, a surfactant, and an optional excipient.
[0020] 3.1 Exemplary Embodiments 1. A pharmaceutical composition for treating non-infectious uveitis in human subjects requiring treatment, (a) A viral capsid that is tropic towards ocular tissue cells, (b) an adeno-associated virus (AAV) vector comprising an artificial genome including an expression cassette adjacent to an AAV internal tandem repeat (ITR), wherein the expression cassette includes a transgene encoding an anti-TNFα Fc fusion protein operably linked to one or more regulatory sequences that control the expression of the transgene in human ophthalmic cells, The pharmaceutical composition wherein the AAV vector is formulated for subretinal, intravitreous, intranasal, intrachorionic, parachoroidal, or systemic administration to the human subject. 2. The pharmaceutical composition according to paragraph 1, comprising a soluble extracellular component of human TNFα receptor type I (TNFR1) or type II (TNFR2), wherein the anti-TNFα Fc fusion protein is covalently bonded via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain. 3. The virus capsid is AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype AAV2.7m8 (AAV2.7m8), serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rh10 (AAVrh10), serotype A pharmaceutical composition according to paragraph 1 or 2, which is at least 95% identical to the amino acid sequence of rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh73 (AAVrh73), serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26). 4. The pharmaceutical composition according to any one of paragraphs 1 to 3, wherein the AAV capsid is AAV8, AAV3B, AAV2.7m8, or AAVrh73. 5. The pharmaceutical composition according to any one of paragraphs 1 to 4, wherein the eye tissue cells are corneal cells, iris cells, ciliary body cells, Schlemm's canal cells, fibromuscular trabecular cells, retinal cells, RPE choroid tissue cells, or optic nerve cells. 6. The pharmaceutical composition according to any one of paragraphs 1 to 5, wherein the regulatory sequence comprises a regulatory sequence from Table 1 or 1b. 7. The pharmaceutical composition according to paragraph 5, wherein the regulatory sequence is a human rhodopsin kinase (GRK1) promoter (SEQ ID NO: 54 or 117), a mouse cone arrestin (CAR) promoter (SEQ ID NO: 114 to 116), a human red opsin (RedO) promoter (SEQ ID NO: 112), a CB promoter (SEQ ID NO: 159), a CB long promoter (SEQ ID NO: 160), or a Best1 / GRK promoter (SEQ ID NO: 161). 8. The pharmaceutical composition according to any one of paragraphs 1 to 7, wherein the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that directs secretion and post-translational modification in the human eye cells. 9. The pharmaceutical composition according to paragraph 8, wherein the signal sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62) or a signal sequence from Table 2, 3, or 4. 10. The pharmaceutical composition according to any one of paragraphs 1 to 8, wherein the transgene has the structure from the N-terminus to the C-terminus: signal sequence - soluble TNFR extracellular domain - hinge region - Fc domain - polyA. 11. The composition according to paragraph 10, wherein the transgene further comprises a thrombin cleavage site of SEQ ID NO: 8 at the C-terminus of the soluble TNFR extracellular domain. 12. The pharmaceutical composition according to any one of paragraphs 1 to 11, wherein the anti-TNFα Fc fusion protein is expressed as a dimeric fusion protein. 13. The pharmaceutical composition according to any one of paragraphs 1 to 12, wherein the anti-TNFα Fc fusion protein is etanercept or EYS606. 14. The pharmaceutical composition according to any one of paragraphs 1 to 13, wherein the introduced gene contains the nucleotide sequences of sequence numbers 15 to 18. 15. The pharmaceutical composition according to any one of paragraphs 1 to 14, wherein the anti-TNFα Fc fusion protein has the amino acid sequence of SEQ ID NO: 10 or 12. 16. The pharmaceutical composition according to any one of paragraphs 1 to 15, wherein the anti-TNFα Fc fusion protein is a highly glycosylated variant, or the Fc polypeptide of the anti-TNFα Fc fusion protein is glycosylated or deglycosylated. 17. The pharmaceutical composition according to any one of paragraphs 1 to 16, wherein the Fc domain is an IgG1-Fc domain. 18. A pharmaceutical composition according to any one of paragraphs 1 to 17, wherein the artificial genome is self-complementary. 19. The pharmaceutical composition according to any one of paragraphs 1 to 18, wherein the artificial genome is constructCAG.etanercept (sequence number 15 or 16) or mU1a.Vh4i.etanercept.scAAV (sequence number 17 or 18). 20. A composition comprising an adeno-associated virus (AAV) vector, a. Optionally, AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype AAV2.7m8 (AAV2.7m8), serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 5 (A AV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rh10 (AAVrh10), serotype The viral AAV capsid is at least 95% identical to the amino acid sequence of rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh73 (AAVrh73), serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26), b. An artificial genome comprising an expression cassette adjacent to an AAV reverse terminal repeat (ITR), wherein the expression cassette comprises a human soluble TNFα receptor type I (TNFR1) or type II (TNFR2) extracellular domain covalently bonded via a peptide bond to a polypeptide comprising an immunoglobulin heavy chain Fc domain, and comprises a transgene encoding an anti-TNF-α Fc fusion protein operably linked to one or more regulatory sequences that promote the expression of the transgene in human ocular tissue cells, The composition wherein the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that directs the secretion and post-translational modification of the anti-TNFα Fc fusion in ocular tissue cells. 21. The composition according to paragraph 20, wherein the transgene further comprises the thrombin cleavage site of SEQ ID NO: 8 at the C-terminus of the soluble human TNFR extracellular domain. 22. The composition according to paragraph 20 or 21, wherein the anti-TNFα Fc fusion protein has the amino acid sequence of SEQ ID NO: 10 or 12. 23. The composition according to any one of paragraphs 20 to 22, wherein the anti-TNFα Fc fusion protein is etanercept or EYS606. 24. The composition according to any one of paragraphs 20 to 23, wherein the ocular tissue cells are corneal cells, iris cells, ciliary body cells, Schlemm's canal cells, trabecular meshwork cells, retinal cells, RPE choroidal tissue cells, or optic nerve cells. 25. The composition according to any one of paragraphs 20 to 24, wherein the introduced gene comprises the nucleotide sequence of SEQ ID NO: 13 or 14. 26. The composition according to any one of paragraphs 20 to 25, wherein the signal sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62) or a signal sequence from Table 2, 3, or 4. 27. The composition according to any one of paragraphs 20 to 26, wherein the artificial genome is self-complementary. 28. The composition according to any one of paragraphs 20 to 27, wherein the artificial genome is constructCAG.etanercept (SEQ ID NO: 15) or mU1a.Vh4i.etanercept.scAAV (SEQ ID NO: 17). Treatment method 29. A method for treating non-infectious uveitis in a human subject requiring treatment, comprising administering a therapeutically effective amount of a composition comprising a recombinant AAV containing a transgene encoding an anti-TNFα Fc fusion protein operably linked to one or more regulatory sequences controlling the expression of a transgene in ocular tissue cells, to the subject subretinal, intravitreous, intranasal, intrachorionic, suprachoroidal, or systemically. 30. A method for treating non-infectious uveitis in a human subject requiring treatment, comprising administering a therapeutically effective amount of a recombinant nucleotide expression vector to the subject subretinal, intravitreous, intranasal, intrachorionic, parachoroidal, or systemically, the vector comprising a transgene encoding an anti-TNFα Fc fusion protein operably linked to one or more regulatory sequences controlling the expression of a transgene in human ocular tissue cells, thereby forming a depot that releases the anti-TNFα Fc fusion protein in human post-translational modification (HuP™) form. 31. The method according to paragraphs 29 and 30, wherein the ocular tissue cells are corneal cells, iris cells, ciliary body cells, Schlemm's canal cells, trabecular meshwork cells, retinal cells, RPE choroidal tissue cells, or optic nerve cells. 32. The method according to any one of paragraphs 29 to 31, wherein the anti-TNFα Fc fusion protein comprises a human soluble TNFα receptor type I (TNFR1) or type II (TNFR2) extracellular domain covalently bound to an IgG Fc domain. 33. The method according to any one of paragraphs 29 to 32, wherein the introduced gene is etanercept or EYS606. 34. The method according to any one of paragraphs 29 to 33, wherein the introduced gene has the nucleotide sequence of SEQ ID NOs. 15 to 17. 35. The recombinant nucleotide expression vector is packaged in rAAV having a viral capsid, and the viral capsid is AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype AAV2.7m8, serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype r The method according to any one of paragraphs 29-34, wherein the amino acid sequence is at least 95% identical to that of h10 (AAVrh10), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh73 (AAVrh73), or serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26). 36. The method according to any one of paragraphs 29, 31-35, wherein the AAV capsid is AAV8, AAV2.7m8, AAV3B, or AAVrh73. 37. The method according to any one of paragraphs 29 to 36, wherein the regulatory sequence includes a regulatory sequence from Table 1 or 1a. 38. The method according to paragraph 37, wherein the regulatory sequence is a human rhodopsin kinase (GRK1) promoter (SEQ ID NO: 54 or 117), a mouse pyramidal arrestin (CAR) promoter (SEQ ID NO: 114-116), a human red opsin (RedO) promoter (SEQ ID NO: 112), a CB promoter (SEQ ID NO: 159), a CB long promoter (SEQ ID NO: 160), or a Best1 / GRK promoter (SEQ ID NO: 161). 39. The method according to any one of paragraphs 29 to 38, wherein the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that is directed toward secretion and post-translational modification in the human eye tissue cells. 40. The method according to paragraph 39, wherein the signal sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62) or a signal sequence from Table 2, 3, or 4. 41. The method according to any one of paragraphs 25-40, wherein the transgene has the following structure: signal sequence-9 human soluble TNFR extracellular domain (type 1 or type 2)-hinge region-Fc domain-polyA. 42. The method according to paragraph 41, wherein the transgene further comprises a thrombin cleavage site having SEQ ID NO: 8 at the C-terminus of the human soluble TNFR extracellular domain. 43. The method according to any one of paragraphs 29 to 42, wherein the anti-TNFα Fc fusion protein is a highly glycosylated mutant, or the Fc domain of the anti-TNFα Fc fusion protein is glycosylated or deglycosylated. 44. The method according to any one of paragraphs 29 to 43, wherein the anti-TNFα Fc fusion protein contains alpha-2,6-sialylated glycan. 45. The method according to any one of paragraphs 29 to 44, wherein the anti-TNFα Fc fusion protein is glycosylated but does not contain detectable NeuGc and / or α-Gal. 46. The method according to any one of paragraphs 29 to 45, wherein the anti-TNFα Fc fusion protein contains tyrosine sulfate. 47. The method according to any one of paragraphs 29 to 46, wherein the production of the HuPTM form of the anti-TNFα Fc fusion protein is confirmed by transduction of the recombinant nucleotide expression vector into human ophthalmic cells in a culture and expression of the anti-TNFα Fc fusion protein. 48. The method according to paragraph 29 or 47, wherein the therapeutically effective dose is determined to be sufficient to improve best corrected visual acuity (BCVA) by two or more ETDRS strains, or to increase logMAR, reduce inflammatory activity in the anterior and posterior chambers according to the SUN classification, and / or reduce the grade of vitreous opacity. 49. The method according to any one of paragraphs 29 to 48, wherein the rAAV is self-complementary. 50. The method according to any one of paragraphs 29 to 49, wherein the transgene is constructCAG.etanercept (sequence number 15 or 16) or mU1a.Vh4i.etanercept.scAAV (sequence number 17 or 18). Manufacturing method 51. A method for producing recombinant AAV, (a) (i) An artificial genome comprising a cis-expression cassette adjacent to an AAV ITR, wherein the cis-expression cassette comprises a transgene encoding an anti-TNFα Fc fusion protein, the anti-TNFα Fc fusion protein comprising a soluble extracellular component of human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently bonded via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain, and operably linked to one or more regulatory sequences that promote the expression of the transgene in human ocular tissue cells, (ii) A trans-expression cassette lacking an AAV ITR, wherein the trans-expression cassette encodes an AAV rep and an AAV capsid protein that are operably linked to an expression control element that drives the expression of the AAV rep and the AAV capsid protein in host cells in a culture and supplies the AAV rep and the AAV capsid protein in trans, and the capsid has ocular tissue tropism, (iii) culturing the host cells containing sufficient adenovirus helper function to enable replication and packaging of the artificial genome by the AAV capsid protein, (b) The method comprising recovering recombinant AAV that forms a capsid of the artificial genome from the cell culture. 52. The method according to paragraph 51, wherein the ocular tissue cells are corneal cells, iris cells, ciliary body cells, Schlemm's canal cells, trabecular meshwork cells, retinal cells, RPE choroidal tissue cells, or optic nerve cells. 53. The transgene encodes etanercept or EYS606, the AAV capsid protein is the rAAV capsid protein of Embodiment 1, and the capsid protein is AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype 2.7m8, serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype The method according to paragraph 51 or 52, wherein the AAV serotype is derived from at least one of the following AAV serotypes: 9e (AAV9e), serotype rh10 (AAVrh10), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh73 (AAVrh73), serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26). 54. Host cells, a. An artificial genome comprising a cis-expression cassette adjacent to an AAV ITR, wherein the cis-expression cassette comprises a transgene encoding an anti-TNFα fusion protein, the anti-TNFα Fc fusion protein comprises a soluble extracellular component of human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently bonded via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain, and is operably linked to one or more regulatory sequences that promote the expression of the transgene in human ocular tissue cells, b. A trans-expression cassette lacking an AAV ITR, wherein the trans-expression cassette encodes an AAV rep and an AAV capsid protein that are operably linked to an expression control element that drives the expression of the AAV rep and the AAV capsid protein in the host cells in the culture and supplies the AAV rep and the AAV capsid protein in trans, and the capsid has ocular tissue tropism, c. The host cell containing sufficient adenovirus helper function to enable replication and packaging of the artificial genome by the AAV capsid protein. 55. The host cell described in paragraph 54, wherein the transgene encodes etanercept or EYS606. 56. The AAV capsid protein may be AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype 2.7m8 (AAV2.7m8), serotype 3 (AAV3), serotype 3B (AAV3B), or serotype 4 (AAV). 4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rh10 (AA) Host cells as described in paragraph 53 or 54, which are serotype Vrh10), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh73 (AAVrh73), serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26). 4. Brief explanation of the drawing [Brief explanation of the drawing]
[0021] [Figure 1] Schematic diagram of an rAAV vector genome construct containing an expression cassette that encodes etanercept, which is controlled by an expression element, adjacent to the AAV ITR. [Figure 2A] Amino acid sequence of the anti-TNFα Fc fusion protein etanercept. Glycosylation sites are shown in bold or underlined. Glutaming glycosylation sites; aspartate (N) glycosylation sites, canonical and unconventional aspartate (N) glycosylation sites; and tyrosine-O-sulfation sites (italicized) are as shown in the legend. Fc domains (CH2 and CH3 domains) are highlighted in gray. Hinge regions are shown in italics. Thrombin cleavage sites are underlined. [Figure 2B]Amino acid sequence of the anti-TNFα Fc fusion protein EYS606. Glycosylation sites are shown in bold or underlined. Glutaming glycosylation sites; aspartate (N) glycosylation sites, canonical and unconventional aspartate (N) glycosylation sites; and tyrosine-O-sulfation sites (italicized) are as shown in the legend. The Fc domain (CH2 and CH3 domains) is highlighted in gray. Hinge regions are shown in italics. Thrombin cleavage sites are underlined. [Figure 3-1] Clusteral multiple sequence alignments of various capsids exhibiting ocular tissue tropism. Amino acid substitutions (shown in bold in the lower row) can be performed on the AAV8 capsid by "recruiting" amino acid residues from corresponding positions in other aligned AAV capsids. Sequences shown in gray = hypervariable regions. The amino acid sequences of AAV capsids are assigned sequence ID numbers as shown in Figure 3. [Figure 3-2] This is a continuation of Figure 3-1. [Figure 3-3] This is a continuation of Figure 3-1. [Figure 3-4] This is a continuation of Figure 3-1. [Figure 3-5] This is a continuation of Figure 3-1. [Figure 3-6] This is a continuation of Figure 3-1. [Figure 3-7] This is a continuation of Figure 3-1. [Figure 4] Clusteral multiple sequence alignment of the constant heavy chain regions (CH2 and CH3) of IgG1 (SEQ ID NO: 47), IgG2 (SEQ ID NO: 48), and IgG4 (SEQ ID NO: 49). The hinge region of the heavy chain from residues 219 to 230 is shown in italics. Amino acid numbering is in EU format. [Figure 5]A. Binding of TNFα across model species (mouse, rat, and human) by vectorized adalimumab IgG and Fab. Negative control included supernatant derived from untransfected cells. Vectorized lanadermab (pAAV.CAG.lanadermab.IgG) served as a nonspecific antibody control. Data are expressed as mean ± SEM. B. Binding of TNFα across model species (mouse, rat, and human) by vectorized adalimumab IgG and etanercept. Negative control included supernatant derived from untransfected cells. Vectorized lanadermab (pAAV.CAG.lanadermab.IgG) served as a nonspecific antibody control. Data are expressed as mean ± SEM. [Modes for carrying out the invention]
[0022] 5. Modes for Carrying Out the Invention This invention describes a systemic composition and method for the delivery of a fully human post-translationally modified (HuP™) therapeutic anti-TNFα Fc fusion protein that binds to TNFα to a human subject diagnosed with non-infectious uveitis. Delivery can be advantageously achieved by administering gene therapy, e.g., a viral vector or other DNA expression construct encoding a therapeutic anti-TNFα Fc fusion protein (or any hyperglycosylated derivative), to a patient (human subject) diagnosed with non-infectious uveitis to create a permanent depot that continuously supplies the HuP™ anti-TNFα Fc fusion protein, e.g., a human glycosylated transgene product, to the site where the anti-TNFα Fc fusion protein exerts its therapeutic effect.
[0023] In certain embodiments, the HuPTM anti-TNFα Fc fusion protein encoded by the transgene is, but is not limited to, a TNFR:Fc fusion protein that binds to TNFα, particularly etanercept or EYS606 (see Figures 2A and 2B for the amino acid sequences of the TNFR-Fc fusion proteins etanercept and EYS606, respectively). In embodiments, when expressed, the TNFR Fc fusion protein is dimerized.
[0024] The HuPTM anti-TNFα Fc fusion protein encoded by the transgene may include, but is not limited to, a therapeutic anti-TNFα TNFR1:Fc fusion that binds to TNFα, including, but not limited to, EYS606. The above amino acid sequences are provided in Table 6 below. The TNFR1 domain has the amino acid sequence of SEQ ID NO: 1, the Fc domain has the amino acid sequence of SEQ ID NO: 6 (or 7 without the hinge), and the EYS606 protein has the amino acid sequence of SEQ ID NO: 12. The HuPTM anti-TNFα TNFR1:Fc fusion product encoded by the transgene may include, but is not limited to, a dimeric fusion protein engineered to include an additional glycosylation site on the Fc domain.
[0025] The HuPTM anti-TNFα Fc fusion protein encoded by the transgene may include, but is not limited to, a therapeutic anti-TNFα TNFR2:Fc fusion that binds to TNFα, including, but not limited to, etanercept. The above amino acid sequences are provided in Table 6 below. A TNFR2 domain having the amino acid sequence of SEQ ID NO: 2, an Fc domain having the amino acid sequence of SEQ ID NO: 3 (SEQ ID NO: 4 without the hinge region), etanercept having the amino acid sequence of SEQ ID NO: 10 (SEQ ID NO: 11 including the leader sequence), and one transgene nucleotide sequence from SEQ ID NOs: 13-18. The HuPTM anti-TNFα TNFR2:Fc fusion protein encoded by the transgene may include, but is not limited to, a dimeric fusion protein engineered to include a further glycosylation site on the Fc domain.
[0026] The compositions and methods provided herein deliver anti-TNFα Fc fusion proteins, particularly etanercept and EYS606, systemically from a viral genome depot to, for example, the eye or liver / muscle of a subject, within ocular tissue (e.g., vitreous fluid or aqueous humor), or in serum, at any level that is therapeutically or prophylactically effective to treat or alleviate symptoms of non-infectious uveitis or other indications that can be treated with anti-TNFα Fc fusion proteins. In embodiments, a viral vector for delivery of a transgene encoding a therapeutic anti-TNFα Fc fusion protein to cells in a human subject, including one or more ocular tissue cells, and regulatory elements operably linked to a nucleotide sequence encoding an anti-TNFα Fc fusion protein that promotes antibody expression in cells, in embodiments, ocular tissue cells, are identified herein. Such regulatory elements, including ocular tissue-specific regulatory elements, are provided herein in Tables 1 and 1a. Therefore, such viral vectors may be delivered to human subjects in an appropriate dose such that the anti-TNFα Fc fusion protein is present in the serum or ocular tissue of the human subject at a therapeutically effective level at least 20, 30, 40, 50, or 60 days after administration. In embodiments, the therapeutically effective level of the anti-TNFα Fc fusion protein is determined (in human clinical trials, or in animal models, e.g., those described herein) for improvement of best corrected visual acuity (BCVA) by two or more ETDRS strains, or for an increase in logMAR, a reduction in anterior and posterior chamber inflammatory activity according to the SUN classification, and / or a reduction in the grade of vitreous opacity.
[0027] Recombinant vectors used to deliver transgenes include non-replicating recombinant adeno-associated virus vectors ("rAAVs"). rAAVs are particularly attractive vectors for several reasons: they can transduce non-replicating cells and therefore can be used to deliver transgenes to tissues where cell division occurs at low levels, such as the retina; they can be modified to preferentially target specific organs of choice; hundreds of capsid serotypes exist to be selected to obtain desired tissue specificity and / or to avoid neutralization by existing patient antibodies against certain AAVs. Such rAAVs include, but are not limited to, AAV-based vectors containing a capsid component from one or more of the following serotypes: AAV1, AAV2, AAV2.7m8, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV9e, AAVrh10, AAVrh20, AAVrh39, AAVhu.37, AAVrh73, AAVrh74, AAV.hu51, AAV.hu21, AAV.hu12, or AAV.hu26. In certain embodiments, the AAV-based vectors provided herein contain a capsid from one or more of the following serotypes: AAV2.7m8, AAV8, AAV9, AAV10, or AAVrh10.
[0028] However, other viral vectors may be used, including but not limited to lentiviral vectors, vaccinia virus vectors, or nonviral expression vectors referred to as "naked DNA" constructs. Transgene expression can be controlled by constitutive or tissue-specific expression regulatory elements.
[0029] The gene therapy construct for therapeutic anti-TNFα Fc fusion proteins is designed so that the covalently bound TNFR and Fc portions are expressed as a dimeric fusion protein. For example, the TNFR:Fc fusion may include all or part of the hinge region (e.g., SEQ ID NO: 5 or 9) linked to the formation of disulfide bonds between the heavy chains. Preferably, TNFR1:Fc is a biobetter or biosimilar of EYS606, or more preferably, TNFR:Fc is EYS606. Preferably, TNFR2:Fc is a biobetter or biosimilar of etanercept, or more preferably, TNFR:Fc is etanercept.
[0030] In certain embodiments, the nucleic acids (e.g., polynucleotides) and nucleic acid sequences disclosed herein may be codon-optimized, for example, via any codon optimization technique known to those skilled in the art (see, for example, the overview in Quax et al., 2015, Mol Cell 59:149-161), and may also be optimized to reduce CpG dimers. Nucleotide sequences of therapeutic anti-TNFα Fc fusion proteins that can be codon-optimized are disclosed in Table 7. Anti-TNFα Fc fusion proteins require an N-terminal leader to ensure proper post-translational processing and secretion. Useful leader sequences for the expression of therapeutic anti-TNFα Fc fusion proteins in human cells are disclosed herein. An exemplary recombinant expression construct is shown in Figure 1.
[0031] The production of HuPTM anti-TNFα Fc fusion protein should result in a "bio-better" molecule for the treatment of diseases achieved through gene therapy. This should be achieved by administering a viral vector encoding the anti-TNFα Fc fusion protein, such as etanercept or EYS606, or another DNA expression construct, to a patient (human subject) diagnosed with the disease indication for the anti-TNFα Fc fusion protein, thereby creating a permanent depot in the subject that continuously supplies the human glycosylated sulfated transgene product produced by the subject's transduced cells. The cDNA construct of HuPTM anti-TNFα Fc fusion protein should include a signal peptide to ensure proper co-translation and post-translational processing (glycosylation and protein sulfated protein) by the transduced human cells.
[0032] Pharmaceutical compositions suitable for administration to human subjects include a suspension of a recombinant vector in a formulation buffer containing a physiologically compatible aqueous buffer, a surfactant, and an optional excipient. Such a formulation buffer may contain one or more of the following: polysaccharides, surfactants, polymers, or oils.
[0033] As an alternative or additional treatment to gene therapy, the full-length HuPTM anti-TNFα Fc fusion protein can be produced in human cell lines by recombinant DNA technology, and the glycoprotein can be administered to patients. Examples of human cell lines that may be used for such recombinant glycoprotein production include, but are not limited to, human embryonic kidney 293 cells (HEK293), fibrosarcoma HT-1080, HKB-11, CAP, HuH-7, and retinal cell lines, PER.C6, or RPE (see, for example, Dumont et al., 2015, Crit. Rev. Biotechnol. 36(6):1110-1122 (the entire overview of human cell lines that may be used for recombinant production of HuPTM biological agents is incorporated by reference)). To ensure complete glycosylation, particularly sialylation, and tyrosine-sulfation, the cell lines used for production may be enhanced by manipulating the host cells to co-express α-2,6-sialyltransferase (or both α-2,3- and α-2,6-sialyltransferases) and / or TPST-1 and TPST-2 enzymes, which are involved in tyrosine-O-sulfation in human cells.
[0034] It is not essential that all molecules produced by either gene therapy or protein therapy approaches be completely glycosylated and sulfated. Rather, the population of glycoproteins produced should have sufficient glycosylation (including 2,6-sialylation) and sulfatedness to demonstrate efficacy. The goal of the gene therapy treatment of this invention is to slow or halt disease progression.
[0035] Combination therapy involving the delivery of HuPTM anti-TNFα Fc fusion protein to patients in conjunction with the administration of other available treatments is included in the method of the present invention. Additional treatments may be administered before, concurrently with, or after gene therapy. Such additional treatments may include, but are not limited to, combination therapy with therapeutic anti-TNFα Fc fusion protein.
[0036] Methods for producing viral vectors, particularly AAV-based viral vectors, are also provided. In certain embodiments, a method for producing recombinant AAV is provided, comprising culturing host cells containing an artificial genome containing an artificial genome with sufficient adenovirus helper function to enable replication and packaging of the artificial genome by the AAV capsid protein; and recovering recombinant AAV from the cell culture that capsids the artificial genome.
[0037] 5.1. Definition The term "anti-TNFα Fc fusion protein" refers to a polypeptide containing a soluble extracellular domain or portion of the TNFα receptor, such as the TNF-α receptor p55 or p75, covalently bonded to the Fc domain of an immunoglobulin, particularly IgG, via a peptide bond.
[0038] The term “regulatory element” or “nucleic acid regulatory element” refers to a non-coding nucleic acid sequence that controls the transcription of an adjacent gene. Cis-regulatory elements typically regulate gene transcription by binding to a transcription factor. This includes “complex nucleic acid regulatory elements” that comprise two or more enhancer or promoter elements as described herein.
[0039] The term “expression cassette” or “nucleic acid expression cassette” refers to a nucleic acid molecule containing one or more transcriptional regulatory elements, including but not limited to promoters, enhancers and / or regulatory elements, introns and polyadenylated sequences. Enhancers and promoters typically function to direct (trans) gene expression in one or more desired cell types, tissues, or organs.
[0040] The terms “operatably linked” and “operatably linked to” refer to nucleic acid sequences that are linked, typically adjacent or substantially adjacent, and, if necessary, adjacent and within the reading frame, where two protein-coding regions need to be joined. However, since enhancers generally function when separated from promoters by only a few kilobases, and intron sequences can be of variable length, some polynucleotide elements may not be directly contiguous with the downstream promoter and transgene, but can still be operationally linked and functional.
[0041] The term "AAV" or "adeno-associated virus" refers to dependent parvoviruses within the Parvoviridae genus. AAVs can be derived from naturally occurring "wild-type" viruses, from rAAV genomes packaged in a capsid containing a capsid protein encoded by a naturally occurring cap gene, and / or from rAAV genomes packaged in a capsid containing a capsid protein encoded by a non-naturally occurring capsid cap gene. An example of the latter is rAAV having a capsid protein that includes peptide insertions or modifications to the amino acid sequence of a naturally occurring capsid.
[0042] The term "rAAV" refers to "recombinant AAV." In some embodiments, recombinant AAV has an AAV genome in which some or all of the rep and cap genes are replaced with heterologous sequences.
[0043] The term "rep-cap helper plasmid" refers to a plasmid that provides viral rep and cap gene function and assists in the production of AAV from rAAV genomes lacking functional rep and / or cap gene sequences.
[0044] The term "cap gene" refers to a nucleic acid sequence that codes for a capsid protein that forms or helps form the capsid coat of a virus. In the case of AAV, the capsid protein may be VP1, VP2, or VP3.
[0045] The term "rep gene" refers to a nucleic acid sequence that encodes a non-structural protein necessary for viral replication and production.
[0046] The terms “nucleic acid” and “nucleotide sequence” include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), combinations of DNA and RNA molecules or hybrid DNA / RNA molecules, and analogues of DNA or RNA molecules. Such analogues can be produced using nucleotide analogues that include, for example, inosine or tritylated bases. Such analogues may also include DNA or RNA molecules that contain a modified backbone that gives the molecule beneficial attributes, for example, nuclease resistance or increased ability to cross the cell membrane. Nucleic acids or nucleotide sequences can be single-stranded or double-stranded, and may contain both single-stranded and double-stranded portions, and may contain triple-stranded portions, but are preferably double-stranded DNA.
[0047] The terms “subject,” “host,” and “patient” are used interchangeably. As used herein, the subject is preferably a mammal such as a non-primate (e.g., cattle, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkeys and humans), most preferably a human.
[0048] The terms “therapeutic agent” or “biotherapeutic agent” refer to any agent that may be used to treat, manage, or alleviate symptoms associated with a disease or disorder, the disease or disorder being associated with a function provided by a transgene. As used herein, “therapeutic effective dose” refers to the amount of an agent (e.g., the amount of product expressed by a transgene) that, when administered to a subject suffering from a target disease or disorder, provides at least one therapeutic benefit in its treatment or management. Furthermore, the therapeutic effective dose for the agents of the present invention means the amount of the agent alone or in combination with other therapies that provides at least one therapeutic benefit in the treatment or management of a disease or disorder.
[0049] The terms "liver-specific" or "liver-targeted" refer to nucleic acid elements whose activity in liver cells or tissues is adapted due to their interaction with the intracellular environment of hepatocytes. In the context of gene therapy delivered to liver tissue, the liver functions as the body's bioreactor or "depot," and gene cassettes enhanced for expression in the liver produce biopharmaceuticals (translated proteins) that are secreted into circulation. Thus, biopharmaceuticals are delivered systemically to the target by hepatic expression. Without being bound by any particular theory, hepatic production of biopharmaceuticals (such as those produced by delivered transgenes) can provide immune tolerance to the drug, so that the endogenous T cells of the target producing the protein do not recognize the protein as a self-protein and do not induce an innate immune response.
[0050] 5.2. Construct Viral vectors or other DNA expression constructs encoding the HuPTM anti-TNFα Fc fusion protein are provided herein. The viral vectors and other DNA expression constructs provided herein include any preferred method for delivering the transgene to target cells. Means of transgene delivery include viral vectors, liposomes, other lipid-containing complexes, other macromolecular complexes, synthetically modified mRNA, unmodified mRNA, small molecules, biologically active molecules (e.g., gold particles), polymerized molecules (e.g., dendrimers), naked DNA, plasmids, phages, transposons, cosmids, or episomes. In some embodiments, the vector is a targeted vector, e.g., a vector that targets ocular tissue cells or a vector that has tropism toward ocular tissue cells.
[0051] In some embodiments, the Disclosure provides nucleic acids for use, the nucleic acids comprising a nucleotide sequence encoding a HuPTM anti-TNFα Fc fusion protein as a transgene described herein, operably linked to a promoter selected for expression in a targeted tissue for transgene expression, e.g., ubiquitous promoters, e.g., the CB7 / CAG promoter (SEQ ID NO: 50) and associated upstream regulatory sequences, the cytomegalovirus (CMV) promoter, the EF-1 alpha promoter (SEQ ID NO: 53), the mU1a (SEQ ID NO: 52), the UB6 promoter, the chicken beta-actin (CBA) promoter, and eye tissue-specific promoters, e.g., the human rhodopsin kinase (GRK1) promoter (SEQ ID NO: 54 or 117), the mouse cone arrestin (CAR) promoter (SEQ ID NO: 114-116), the human red opsin (RedO) promoter (SEQ ID NO: 112), the CB promoter (SEQ ID NO: 159), the CB long promoter (SEQ ID NO: 160), or the Best1 / GRK promoter (SEQ ID NO: 161). For a list of useful promoters, please refer to Tables 1 and 1a.
[0052] In certain embodiments, recombinant vectors comprising one or more nucleic acids (e.g., polynucleotides) are provided herein. The nucleic acids may include DNA, RNA, or a combination of DNA and RNA. In certain embodiments, the DNA comprises one or more sequences selected from the group consisting of a promoter sequence, a sequence of the gene of interest (a transgene, e.g., a nucleotide sequence encoding the HuPTM anti-TNFα Fc fusion protein), an untranslated region, and a stop sequence. In certain embodiments, the viral vector provided herein comprises a promoter operably ligated to the gene of interest.
[0053] In certain embodiments, the nucleic acids (e.g., polynucleotides) and nucleic acid sequences disclosed herein may be codon-optimized, for example, via any codon optimization technique known to those skilled in the art (see, for example, the overview in Quax et al., 2015, Mol Cell 59:149-161). Nucleotide sequences for the expression of anti-TNFα fusion proteins in human cells are provided herein in Table 7.
[0054] In certain embodiments, the construct described herein comprises the following components: (1) an AAV2 reverse terminal repeat adjacent to an expression cassette; (2) one or more regulatory elements; b) optionally chicken β-actin or other introns; and c) a rabbit β-globin polyA signal; and (3) a nucleic acid sequence encoding a soluble extracellular domain of TNFR2 ligated to the N-terminus of a human IgG1 Fc domain, the Fc domain comprising a hinge region-CH2 domain-CH3 domain (etanercept) from the N-terminus to the C-terminus. Exemplary constructs are shown in Figures 1 and 2A.
[0055] In certain embodiments, the construct described herein comprises the following components: (1) an AAV2 reverse terminal repeat adjacent to an expression cassette; (2) one or more regulatory elements; b) optionally chicken β-actin or other introns; and c) a rabbit β-globin polyA signaling molecule; and (3) a nucleic acid sequence encoding a soluble extracellular domain of TNFR1 ligated to the N-terminus of a human IgG1 Fc domain via a thrombin cleavage site, wherein the Fc domain comprises a hinge region-CH2 domain-CH3 domain (EYS060) from the N-terminus to the C-terminus. An exemplary construct is shown in Figure 2B.
[0056] 5.2.1 mRNA vectors In certain embodiments, as an alternative to DNA vectors, the vector provided herein is a modified mRNA encoding the gene of interest (e.g., a transgene, e.g., a HuPTM non-monoclonal antibody biologic). The synthesis of modified and unmodified mRNAs for the delivery of transgenes to retinal pigment epithelial cells is described, for example, in Hansson et al., J. Biol. Chem., 2015, 290(9):5661-5672 (which is incorporated herein by reference in its entirety). In certain embodiments, a modified mRNA encoding a HuPTM anti-TNFα Fc fusion protein is provided herein.
[0057] 5.2.2 Viral vectors Viral vectors include adenoviruses, adeno-associated viruses (AAVs, e.g., AAV2.7m8, AAV3, AAV8, AAV9, AAVrh10, AAV2.7m8, and other serotypes), lentiviruses, helper-dependent adenoviruses, herpes simplex viruses, poxviruses, Sendai virus (hemagglutinin virus of Japan (HVJ)), alphaviruses, vaccinia viruses, and retroviral vectors. Retroviral vectors include mouse leukemia virus (MLV) and human immunodeficiency virus (HIV)-based vectors. Alphaviral vectors include Semryki forest virus (SFV) and Sindbis virus (SIN). In certain embodiments, the viral vectors provided herein are recombinant viral vectors. In certain embodiments, the viral vectors provided herein are modified so that they are replication-deficient in humans. In certain embodiments, the viral vector is a hybrid vector, e.g., an AAV vector placed in a “non-responsive” adenovirus vector. In certain embodiments, a viral vector comprising a viral capsid from a first virus and a viral envelope protein from a second virus is provided herein. In certain embodiments, the second virus is vesicular stomatitis virus (VSV). In more specific embodiments, the envelope protein is VSV-G protein.
[0058] In certain embodiments, the viral vector provided herein is an HIV-based viral vector. In certain embodiments, the HIV-based vector provided herein comprises at least two polynucleotides, wherein the gag and pol genes are derived from the HIV genome and the env gene is derived from another virus.
[0059] In certain embodiments, the viral vectors provided herein are herpes simplex virus-based viral vectors. In certain embodiments, the herpes simplex virus-based vectors provided herein are modified so that they do not contain one or more initial (IE) genes, thereby making them non-cytotoxic.
[0060] In certain embodiments, the viral vector provided herein is an MLV-based viral vector. In certain embodiments, the MLV-based vector provided herein contains up to 8 kb of heterologous DNA instead of viral genes.
[0061] In certain embodiments, the viral vector provided herein is a lentivirus-based viral vector. In certain embodiments, the lentivirus vector provided herein is derived from a human lentivirus. In certain embodiments, the lentivirus vector provided herein is derived from a non-human lentivirus. In certain embodiments, the lentivirus vector provided herein is packaged in a lentivirus capsid. In certain embodiments, the lentivirus vector provided herein includes one or more of the following elements: a long terminal repeat, a primer binding site, a polypurine tube, an att site, and a capsid-forming site.
[0062] In certain embodiments, the viral vector provided herein is an alphavirus-based viral vector. In certain embodiments, the alphavirus vector provided herein is a recombinant replication-deficient alphavirus. In certain embodiments, the alphavirus replicon within the alphavirus vector provided herein targets a specific cell type by displaying a functional heterologous ligand on its virion surface.
[0063] In certain embodiments, the viral vector provided herein is an AAV-based viral vector. In certain embodiments, the AAV-based vector provided herein does not encode the AAV rep gene (required for replication) and / or the AAV cap gene (required for the synthesis of the capsid protein) (the rep and cap proteins may be provided by packaging cells in trans). Multiple AAV serotypes have been identified. In certain embodiments, the AAV-based vector provided herein contains components from one or more serotypes of AAV. In preferred embodiments, the AAV-based vector provided herein contains components from one or more serotypes of AAV having tropism to eye tissue, liver, and / or muscle. Throughout this specification, AAV “serotype” refers to AAV having immunologically distinct capsids, naturally occurring capsids, or engineered capsids. In certain embodiments, the AAV-based vectors provided herein include a capsid component from one or more of the following serotypes: AAV1, AAV2, AAV2.7m8, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV9e, AAVrh10, AAVrh20, AAVrh39, AAVhu.37, AAVrh73, AAVrh74, AAV.hu51, AAV.hu21, AAV.hu12, or AAV.hu26. In certain embodiments, the AAV-based vectors provided herein include a component from one or more of the following serotypes: AAV2.7m8, AAV8, AAV3B, AAV9, AAV10, AAVrh73, or AAVrh10.The present invention provides a viral vector in which the capsid protein is a variant of AAV8 capsid protein (SEQ ID NO: 32), AAV3B capsid protein (SEQ ID NO: 26), or AAVrh73 capsid protein (SEQ ID NO: 38), and the capsid protein is at least 95%, 96%, 97%, 98%, 99%, or 99.9% identical in amino acid sequence to, for example, AAV8 capsid protein (SEQ ID NO: 32), AAV3B capsid protein (SEQ ID NO: 26), or AAVrh73 capsid protein (SEQ ID NO: 38), while retaining the biological function of the natural capsid. In certain embodiments, the encoded AAV capsid has the sequence of SEQ ID NO: 32 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions, retaining the biological function of the AAV8, AAV3B, or AAVrh73 capsid. Figure 3 provides comparative alignments of amino acid sequences of capsid proteins of different AAV serotypes with potential amino acids that may be substituted at specific positions in the aligned sequences, based on a row-labeled SUBS comparison. Therefore, in certain embodiments, the AAV vector includes an AAV8, AAV3B, or AAVrh73 capsid variant having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions that are not present at the positions of the native AAV capsid sequence identified in the SUBS row of Figure 3. The amino acid sequences of the AAV8, AAV3B, or AAVrh73 capsid are provided in Figure 3.
[0064] In some embodiments, the AAV-based vector comprises components from one or more serotypes of AAV. In some embodiments, the AAV-based vectors provided herein include AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV.PHP.eB, A Contains a capsid component from one or more of the following: AV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, or AAV.HSC16, or other rAAV particles, or a combination of two or more of these. In some embodiments, the AAV-based vectors provided herein are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV.PHP.eB, Contains components from one or more of the following rAAV particles, or combinations of two or more serotypes: AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, or AAV.HSC16, or other rAAV particles.In some embodiments, the rAAV particles include, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AA V.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, rAAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV. PHP.eB, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, A The VP1, VP2 and / or VP3 sequences of AAV capsid serotypes selected from AV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, or AAV.HSC16, or their derivatives, modifications, or pseudotypes, are at least 80% identical, e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e., contain capsid proteins that are up to 100% identical.
[0065] In certain embodiments, the recombinant AAV for use in the compositions and methods herein is Anc80 or Anc80L65 (see, for example, Zinn et al., 2015, Cell Rep. 12(6):1056-1068 (which is incorporated in whole by reference)). In certain embodiments, the recombinant AAV for use in the compositions and methods herein is AAV.7m8 (including its variants) (see, for example, US9,193,956, US9,458,517, US9,587,282, US2016 / 0376323, and WO2018 / 075798 (each of which is incorporated in whole by reference)). In certain embodiments, the AAV for use in the compositions and methods herein is any AAV disclosed in US9,585,971, such as AAV-PHP.B. In certain embodiments, the AAV for use in the compositions and methods herein is an AAV2 / Rec2 or AAV2 / Rec3 vector having a hybrid capsid sequence derived from AAV8 and serotype cy5, rh20, or rh39 (see, for example, Issa et al., 2013, PLoS One 8(4):e60361 (these vectors are incorporated herein by reference)). In certain embodiments, the AAV for use in the compositions and methods herein is an AAV disclosed in any of the following, each of which is incorporated herein by reference in its entirety: US7,282,199, US7,906,111, US8,524,446, US8,999,678, US8,628,966, US8,927,514, US8,734,809, US9,284,357, U S9,409,953, US9,169,299, US9,193,956, US9,458,517, US9,587,282, US2015 / 0374803, US2015 / 0126588, US2017 / 0067908, US2013 / 0224836, US2016 / 0215024, US2017 / 0051257, PCT / US2015 / 034799, and PCT / EP2015 / 053335.In some embodiments, the rAAV particles have at least 80% identical capsid proteins to the VP1, VP2, and / or VP3 sequences of AAV capsids disclosed in any of the following patents and patent applications, e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e., up to 100% identical capsid proteins, each of which is incorporated herein by reference in whole: U.S. Patent No. 7,282,199, No. 7,906,111, No. 8,524,446, No. 8,999,678, No. 8 US Patent Nos. 628,966, 8,927,514, 8,734,809, US Nos. 9,284,357, 9,409,953, 9,169,299, 9,193,956, 9,458,517, and 9,587,282; US Patent Application No. 2015 / 03748 Patent applications No. 03, No. 2015 / 0126588, No. 2017 / 0067908, No. 2013 / 0224836, No. 2016 / 0215024, No. 2017 / 0051257; and international patent applications PCT / US2015 / 034799 and PCT / EP2015 / 053335.
[0066] In some embodiments, the rAAV particles include any AAV capsid disclosed in U.S. Patent No. 9,840,719 and WO2015 / 013313 (each of which is incorporated herein by reference in its entirety) (e.g., AAV.Rh74 and RHM4-1). In some embodiments, the rAAV particles include any AAV capsid disclosed in WO2014 / 172669 (each of which is incorporated herein by reference in its entirety) (e.g., AAVrh.74). In some embodiments, the rAAV particles include the AAV2 / 5 capsid described in Georgiadis et al., 2016, Gene Therapy 23:857-862 and Georgiadis et al., 2018, Gene Therapy 25:450 (each of which is incorporated herein by reference in its entirety). In some embodiments, the rAAV particles include any AAV capsid (e.g., AAV2tYF) disclosed in WO2017 / 070491 (which is incorporated herein in its entirety by reference). In some embodiments, the rAAV particles include a capsid of AAVLK03 or AAV3B as described in Puzzo et al., 2017, Sci. Transl. Med. 29(9):418 (which is incorporated herein in its entirety by reference). In some embodiments, the rAAV particles include any AAV capsid disclosed in U.S. Patent No. 8,628,966, U.S. 8,927,514, U.S. 9,923,120 and WO2016 / 049230 (each of which is incorporated in whole by reference) (e.g., HSC1, HSC2, HSC3, HSC4, HSC5, HSC6, HSC7, HSC8, HSC9, HSC10, HSC11, HSC12, HSC13, HSC14, HSC15, or HSC16).
[0067] In some embodiments, rAAV particles are represented by International Patent Publication No. WO2003 / 052051 (see, for example, SEQ ID NO. 2 in Publication '051), WO2005 / 033321 (see, for example, SEQ ID NOs. 123 and 88 in Publication '321), WO03 / 042397 (see, for example, SEQ ID NOs. 2, 81, 85, and 97 in Publication '397), WO2006 / 068888 (see, for example, SEQ ID NOs. 1 and 3-6 in Publication '888), WO2006 / 110689 (see, for example, SEQ ID NOs. 5-38 in Publication '689), WO200 The capsid protein is disclosed in 9 / 104964 (see, for example, SEQ ID NOs. 1-5, 7, 9, 20, 22, 24 and 31 of '964), WO2010 / 127097 (see, for example, SEQ ID NOs. 5-38 of '097), and WO2015 / 191508 (see, for example, SEQ ID NOs. 80-294 of '508), and U.S. Patent Publication No. 2015 / 0023924 (see, for example, SEQ ID NOs. 1, 5-10 of '924) (the contents of each thereof are incorporated herein by reference in their entirety).In some embodiments, the rAAV particles are represented by International Patent Publication No. WO2003 / 052051 (see, for example, SEQ ID NO: 2 in Publication '051), WO2005 / 033321 (see, for example, SEQ ID NOs: 123 and 88 in Publication '321), WO03 / 042397 (see, for example, SEQ ID NOs: 2, 81, 85, and 97 in Publication '397), WO2006 / 068888 (see, for example, SEQ ID NOs: 1 and 3-6 in Publication '888), WO2006 / 110689 (see, for example, SEQ ID NOs: 5-38 in Publication '689), and WO2009 / 104964 (see, for example, SEQ ID NOs: 1-5, 7, 9, 20, 22, 24, and 31 in Publication 964). The AAV capsids disclosed in U.S. Patent Publication No. 2015 / 0023924 (see, for example, SEQ ID NOs. 5-38 in publication '097) and WO2015 / 191508 (see, for example, SEQ ID NOs. 80-294 in publication '508) and U.S. Patent Publication No. 2015 / 0023924 (see, for example, SEQ ID NOs. 1, 5-10 in publication '924) have at least 80% identical capsid proteins, e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e., up to 100% identical capsid proteins.
[0068] In additional embodiments, the rAAV particles include a pseudotyped AAV capsid. In some embodiments, the pseudotyped AAV capsid is an rAAV2 / 8 or rAAV2 / 9 pseudotyped AAV capsid. Methods for producing and using pseudotyped rAAV particles are known in the art (see, for example, Duan et al., J. Virol., 75:7662-7671 (2001), Halbert et al., J. Virol., 74:1524-1532 (2000), Zolotukhin et al., Methods 28:158-167 (2002), and Auricchio et al., Hum. Molec. Genet. 10:3075-3081 (2001)).
[0069] AAV2.7m8-based, AAV8-based, AAV9-based, and AAVrh10-based viral vectors are used in specific methods described herein. Nucleotide sequences of AAV-based viral vectors, as well as methods for producing recombinant AAV and AAV capsids, are described, for example, in U.S. Patents 9,193,956B2, 7,282,199B2, 7,790,449B2, 8,318,480B2, 8,962,332B2, and International Patent Application No. PCT / EP2014 / 076466 (each of which is incorporated herein in whole by reference). In one embodiment, AAV (e.g., AAV2.7m8, AAV8, AAV9, or AAVrh10)-based viral vectors encoding a transgene (e.g., HuPTM dimer fusion protein) are provided herein. The amino acid sequences of AAV capsids, including AAV2.7m8, AAV8, AAV9, and AAVrh10, are provided in Figure 3.
[0070] In certain embodiments, single-stranded AAVs (ssAAVs) may be used as described above. In certain embodiments, self-complementary vectors, such as scAAVs, may be used (see, for example, Wu, 2007, Human Gene Therapy, 18(2):171-82; McCarty et al, 2001, Gene Therapy, Vol 8, Number 16, Pages 1248-1254; and U.S. Patents No. 6,596,535; No. 7,125,717; and No. 7,456,683 (each of which is incorporated herein by reference in its entirety)).
[0071] In certain embodiments, the viral vector used in the method described herein is an adenovirus-based viral vector. Recombinant adenovirus vectors can be used to deliver the HuPTM anti-TNFα Fc fusion protein within a transgene. Recombinant adenoviruses can be first-generation vectors with or without an E1 deletion, or with an E3 deletion, and with an expression cassette inserted into either deletion region. Recombinant adenoviruses can be second-generation vectors containing complete or partial deletions of the E2 and E4 regions. Helper-dependent adenoviruses retain only the adenovirus reverse terminal repeat and packaging signal (phi). The transgene is inserted between the packaging signal and the 3'ITR and may or may not contain a stuffer sequence to maintain the genome at approximately 36 kb, near the wild-type size. An exemplary protocol for producing adenovirus vectors can be found in Alba et al., 2005, “Gutless adenovirus: last generation adenovirus for gene therapy,” Gene Therapy 12:S18-S27 (the entire protocol is incorporated herein by reference).
[0072] In certain embodiments, the viral vector used in the method described herein is a lentivirus-based viral vector. Recombinant lentiviral vectors can be used to deliver the HuPTM anti-TNFα Fc fusion protein within a transgene. Four plasmids are used to construct the construct: a Gag / pol sequence containing the plasmid, a Rev sequence containing the plasmid, an envelope protein (e.g., VSV-G) containing the plasmid, and a cis-plasmid having a packaging element and the anti-TNFα Fc fusion protein.
[0073] For lentiviral vector production, four plasmids are co-transfected into cells (e.g., HEK293-based cells), thereby allowing the use of polyethyleneimine or calcium phosphate as transfection agents, among other things. The lentivirus is then collected in the supernatant (cell collection is unnecessary / should not be performed as the lentivirus needs to budding from the cells to be active). The supernatant is filtered (0.45 μm), and then magnesium chloride and benzonase are added. Further downstream processes can vary considerably, with the use of TFF and column chromatography being the most GMP-compatible. Others use ultracentrifugation with or without column chromatography. Exemplary protocols for lentiviral vector production can be found in Lesch et al., 2011, “Production and purification of lentiviral vector generated in 293T suspension cells with baculoviral vectors,” Gene Therapy 18:531-538, and Ausubel et al., 2012, “Production of CGMP-Grade Lentiviral Vectors,” Bioprocess Int. 10(2):32-43 (both are incorporated herein by reference in their entirety).
[0074] In certain embodiments, the vector for use in the method described herein is a vector encoding a HuPTM anti-TNFα Fc fusion protein such that, upon introduction of the vector into the relevant cells, the glycosylated and / or tyrosine-sulfated variant of the HuPTM anti-TNFα Fc fusion protein is expressed by the cells.
[0075] 5.2.3 Gene expression promoters and modifiers In certain embodiments, the vectors provided herein include components that regulate gene delivery or gene expression (e.g., “expression regulatory elements”). In certain embodiments, the vectors provided herein include components that regulate gene expression. In certain embodiments, the vectors provided herein include components that affect binding to or targeting of cells. In certain embodiments, the vectors provided herein include components that affect the localization of polynucleotides (e.g., transgenes) within cells after uptake. In certain embodiments, the vectors provided herein include components that can be used, for example, as detectable or selectable markers for detecting or selecting cells that have taken up polynucleotides.
[0076] In certain embodiments, the viral vector provided herein comprises one or more promoters that control the expression of the transgene. These promoters (and other transcription-controlling regulatory elements such as enhancers) may be constitutive (promoting ubiquitous expression) or may be specifically or selectively expressed in ocular tissue. In certain embodiments, the promoter is a constitutive promoter.
[0077] In certain embodiments, the promoter is CB7 (also referred to as the CAG promoter) (see Dinculescu et al., 2005, Hum Gene Ther 16:649-663 (the entire text is incorporated herein by reference)). In some embodiments, the CAG (SEQ ID NO: 51) or CB7 promoter (SEQ ID NO: 50) includes other regulatory elements that enhance the expression of the vector-driven transgene. In certain embodiments, the other regulatory elements include chicken β-actin introns and / or rabbit β-globin polyA signaling rings (SEQ ID NO: 55). In certain embodiments, the promoter includes a TATA box. In certain embodiments, the promoter includes one or more elements. In certain embodiments, one or more promoter elements may be oriented in opposite directions or moved relative to each other. In certain embodiments, the elements of the promoter are arranged to function cooperatively. In certain embodiments, the elements of the promoter are arranged to function independently. In certain embodiments, the viral vector provided herein comprises one or more promoters selected from the group consisting of the human CMV earliest gene promoter, the SV40 early promoter, the Roussarcoma virus (RS) long-terminal repeat, and the rat insulin promoter. In certain embodiments, the vector provided herein comprises one or more long-terminal repeat (LTR) promoters selected from the group consisting of AAV, MLV, MMTV, SV40, RSV, HIV-1, and HIV-2 LTR.
[0078] In certain embodiments, the vectors provided herein include one or more tissue-specific promoters (e.g., retina-specific promoters). In certain embodiments, the viral vectors provided herein include ocular tissue cell-specific promoters such as the human rhodopsin kinase (GRK1) promoter (SEQ ID NO: 54 or 117), the mouse cone arrestin (CAR) promoter (SEQ ID NOs: 114-116), the human red opsin (RedO) promoter (SEQ ID NO: 112), or the Best1 / GRK promoter (SEQ ID NO: 161).
[0079] The invention provides nucleic acid regulatory elements that are chimeric with respect to the tandem sequence of elements within an expression cassette. Generally, regulatory elements have multiple functions, such as transcription initiation or regulation, coordination with cell-specific mechanisms to drive expression during signal transduction, and recognition sites to enhance the expression of downstream genes.
[0080] In certain embodiments, the promoter is an inductive promoter. In certain embodiments, the promoter is a hypoxia-inducible promoter. In certain embodiments, the promoter includes a hypoxia-inducible factor (HIF) binding site. In certain embodiments, the promoter includes a HIF-1α binding site. In certain embodiments, the promoter includes a HIF-2α binding site. In certain embodiments, the HIF binding site includes an RCGTG motif. For further details regarding the location and sequence of the HIF binding site, see, for example, Schodel, et al., Blood, 2011, 117(23):e207-e217 (which is incorporated herein by reference in its entirety). In certain embodiments, the promoter includes binding sites for hypoxia-inducible transcription factors other than HIF transcription factors. In certain embodiments, the viral vector provided herein includes one or more IRES sites that are preferentially translated under hypoxic conditions. For teachings regarding hypoxia-inducible gene expression and the factors involved, see, for example, Kenneth and Rocha, Biochem J., 2008, 414:19-29 (which is incorporated herein by reference in its entirety). In certain embodiments, the hypoxia-inducible promoter is either the human N-WASP promoter (see, for example, Salvi, 2017, Biochemistry and Biophysics Reports 9:13-21 (which is incorporated by reference for teachings on the N-WASP promoter)) or the human Epo hypoxia-inducible promoter (see, for example, Tsuchiya et al., 1993, J. Biochem. 113:395-400 (which is incorporated by reference for disclosures on the Epo hypoxia-inducible promoter)). In other embodiments, the promoter is a drug-inducible promoter, such as a promoter induced by administration of rapamycin or an analogue thereof.See, for example, PCT Publications WO94 / 18317, WO96 / 20951, WO96 / 41865, WO99 / 10508, WO99 / 10510, WO99 / 36553, and WO99 / 41258, as well as US7,067,526 (these in their entirety are incorporated herein by reference for the disclosure of drug-inducible promoters).
[0081] This specification provides constructs containing certain ubiquitous and tissue-specific promoters. Such promoters include synthetic promoters and tandem promoters. Examples of promoters and their nucleotide sequences are provided in Tables 1 and 1a below. Table 1 also includes nucleotide sequences of other regulatory elements useful for expression cassettes provided herein. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8]
[0082] In certain embodiments, the viral vector provided herein includes one or more regulatory elements other than a promoter. In certain embodiments, the viral vector provided herein includes an enhancer. In certain embodiments, the viral vector provided herein includes a repressor. In certain embodiments, the viral vector provided herein includes an intron (e.g., a VH4 intron (SEQ ID NO: 57) or a chimeric intron (SEQ ID NO: 56)). The viral vector may also include a Kozak sequence to facilitate the translation of a transgene product, such as GCCACC.
[0083] In certain embodiments, the viral vectors provided herein include a polyadenylation sequence downstream of the coding region of the transgene. Any polyA site that signals the termination of transcription and directs the synthesis of a polyA tail is suitable for use in the AAV vectors of this disclosure. Exemplary polyA signals are derived from, but are not limited to, the late SV40 gene, the rabbit β-globin gene (SEQ ID NO: 55), the bovine growth hormone (BPH) gene, the human growth hormone (hGH) gene, the synthetic polyA (SPA) site, and the bovine growth hormone (bGH) gene. See, for example, Powell and Rivera-Soto, 2015, Discov. Med., 19(102):49-57.
[0084] The present invention provides a gene expression cassette and a gene expression cassette comprising a gene expression cassette in which the expression of the introduced gene is controlled by an engineered nucleic acid regulatory element having two or more regulatory elements (promoters or enhancers).
[0085] 5.2.4 Signal Peptides In certain embodiments, the vector provided herein includes components that regulate protein delivery. In certain embodiments, the viral vector provided herein includes one or more signal peptides encoding nucleotide sequences, which are fused to a nucleotide sequence encoding an anti-TNFα Fc fusion protein, such that the protein expressed from the transgene has a signal sequence at its N-terminus for secretion. The signal peptide may also be referred to herein as a “leader sequence” or “leader peptide.” In certain embodiments, the signal peptide enables the transgene product to achieve appropriate packaging (e.g., glycosylation) within the cell. In certain embodiments, the signal peptide enables the transgene product to achieve appropriate localization within the cell. In certain embodiments, the signal peptide enables the transgene product to achieve secretion from the cell.
[0086] There are two common approaches to selecting signal sequences for protein production in gene therapy contexts or cell cultures. One approach is to use a signal peptide from a protein homologous to the protein being expressed. For example, a human antibody signal peptide may be used to express IgG in CHO or other cells. Another approach is to identify a signal peptide optimized for the specific host cell used for expression. Signal peptides can be exchanged between different proteins, or even between proteins of different organisms, but typically the signal sequence of the most abundant secreted protein of that cell type is used for protein expression. For example, the signal peptide of human albumin, the most abundant protein in plasma, has been found to substantially increase the rate of protein production in CHO cells. However, certain signal peptides may retain their function and exert activity after being cleaved from the expressed protein as a "post-targeted function." Therefore, in certain embodiments, the signal peptide is selected from the signal peptides of the most abundant protein secreted by the cell used for expression to avoid post-targeted function. In certain embodiments, the signal sequence is fused to both the heavy chain and light chain sequences. An exemplary sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62), which can be encoded by the nucleotide sequence of SEQ ID NO: 63 (see Table 2, Figures 2A and B). Alternatively, Table 2 below provides signal sequences suitable for expression that can induce selective or directed expression of the HuPTM anti-TNFα Fc fusion protein in eye (ocular tissue). Signal sequences active in liver (Table 3) and muscle (Table 4) cells are also provided. [Table 3] [Table 4-1] [Table 4-2] [Table 5]
[0087] 5.2.5 Untranslated Areas In certain embodiments, the viral vector provided herein includes one or more untranslated regions (UTRs), e.g., 3' and / or 5' UTRs. In certain embodiments, the UTRs are optimized with respect to a desired protein expression level. In certain embodiments, the UTRs are optimized with respect to the half-life of the transgene mRNA. In certain embodiments, the UTRs are optimized with respect to the stability of the transgene mRNA. In certain embodiments, the UTRs are optimized with respect to the secondary structure of the transgene mRNA.
[0088] 5.2.6 Reverse terminal repetition In certain embodiments, the viral vectors provided herein include one or more reverse-terminal repeat (ITR) sequences. The ITR sequences may be used to package recombinant gene expression cassettes into virions of the viral vector. In certain embodiments, the ITRs are derived from AAVs, e.g., AAV8 or AAV2 (see, e.g., Yan et al., 2005, J. Virol., 79(1):364-379; U.S. Patent Nos. 7,282,199B2, 7,790,449B2, 8,318,480B2, 8,962,332 B2 and International Patent Application No. PCT / EP2014 / 076466 (each of which is incorporated herein in whole by reference)). In preferred embodiments, the nucleotide sequence encoding the ITR may include, for example, the nucleotide sequence of SEQ ID NO: 58 (5′-ITR) or 60 (3′-ITR). In certain embodiments, self-complementary vectors, such as modified ITRs used to produce scAAV, may be used (see, for example, Wu, 2007, Human Gene Therapy, 18(2):171-82; McCarty et al, 2001, Gene Therapy, Vol 8, Number 16, Pages 1248-1254; and U.S. Patents 6,596,535; 7,125,717; and 7,456,683 (each of which is incorporated herein by reference in whole)). In preferred embodiments, the nucleotide sequence encoding the modified ITR may include, for example, the nucleotide sequence of SEQ ID NO: 58 (5'-ITR) or 60 (3'-ITR), or may be modified for scAAV, SEQ ID NO: 59 (m 5'ITR), or SEQ ID NO: 61 (m 3'ITR).
[0089] 5.2.7 Transgenes The transgene encodes a HuPTM anti-TNFα Fc fusion protein, e.g., a TNFR1:Fc fusion protein or a TNFR2:Fc fusion protein, based on the therapeutic anti-TNFα Fc fusion protein disclosed herein. In certain embodiments, the HuPTM anti-TNFα Fc fusion protein is engineered to include an additional glycosylation site on the TNFR and / or Fc domain. In addition, the Fc domain of the anti-TNFα Fc fusion protein may be engineered to prevent glycosylation at N297 by modifying the glycosylation site (e.g., knocking out the glycosylation site by substitution with another amino acid at N297 and / or substitution with a non-T or S residue at T297). Such an Fc domain is “deglycosylated”.
[0090] 5.2.7.1 Construct for the expression of HuPTM TNFR:Fc fusion protein In certain embodiments, the transgene encodes an anti-TNFα fusion protein, which comprises, for example, a soluble extracellular component of human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently bonded via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain.
[0091] In certain embodiments, the transgene encodes all or part of the extracellular domain or TNFα binding moiety of TNFR2 (SEQ ID NO: 2) fused to all or part of the Fc domain (e.g., including the hinge, CH2, and CH3 domains) of the immunoglobulin heavy chain (SEQ ID NO: 3 or 4). In preferred embodiments, the transgene encodes an anti-TNFα Fc fusion protein, which comprises the human soluble extracellular domain of TNFR2 covalently bonded to the Fc domain (including the heavy chain CH2 and CH3, and the hinge region) of human IgG1, for example, via peptide bonds, to associate at expression to form a dimeric TNFR2:Fc fusion protein. In particular, the anti-TNFα Fc fusion protein is etanercept (having the amino acid sequence of SEQ ID NO: 10 or 11 along with the leader sequence), or any biosimilar form of etanercept, including etanercept-szzs (ERELZI®) and etanercept-ykro (ETICOVO®).
[0092] In other embodiments, the transgene encodes all or part of the soluble extracellular domain of TNFR1 (SEQ ID NO: 1) fused to all or part of the immunoglobulin heavy chain Fc domain (SEQ ID NO: 6 or 7). In preferred embodiments, the transgene encodes an anti-TNFα Fc fusion protein, which includes the human soluble extracellular domain of TNFR1 covalently bonded to the Fc portion of human IgG1 (including heavy chain CH2 and heavy chain CH3 and the hinge region), for example via a peptide bond, to associate at expression to form a dimeric TNFR1:Fc fusion protein (SEQ ID NO: 12). In some embodiments, TNFR1 is fused to the Fc domain via the thrombin cleavage site LVPRGS (SEQ ID NO: 8). In certain embodiments, the anti-TNFα Fc fusion protein is EYS060 (having the amino acid sequence of SEQ ID NO: 12).
[0093] The recombinant AAV construct expresses the HuPTM anti-TNFα Fc fusion protein in cells, cell cultures, or subjects. The nucleotide sequences encoding the soluble extracellular domains of the TNFR and Fc domains may be codon-optimized for expression in human cells, and the incidence of CpG dimers in the sequences may be reduced to promote expression in human cells. In preferred embodiments, the transgene encodes one of the therapeutic anti-TNFα Fc fusion proteins disclosed herein, for example, the TNFR:Fc fusion proteins shown in Figure 1 or 2 (sequences provided in Figures 2A and 2B).
[0094] In certain embodiments, the Fc domain is an IgG Fc domain, while in other embodiments, the Fc region may be IgA, IgD, IgE, or IgM. The Fc fusion protein expressed from the transgene may have an IgG1, IgG2, IgG3, or IgG4 Fc domain, but is preferably derived from human IgG1. The Fc domain may include some or all of the heavy chain CH1, hinge, CH2, and CH3 domains described herein (see Figure 4 and Table 5), or fragments or variants thereof.
[0095] The Fc domain of the Fc fusion protein has one or more effector functions that vary with the antibody isotype. The effector functions are the same as those of the wild-type or therapeutic Fc fusion protein, or they can be modified to add, enhance, modify, or inhibit one or more effector functions using the Fc modifications disclosed in Section 5.2.8 below. In certain embodiments, the HuPTM non-monoclonal antibody transgene encodes a fusion protein comprising an Fc polypeptide containing an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the Fc domain polypeptide of the therapeutic fusion protein described herein shown in Table 6 for etanercept, or the exemplary Fc domain of the IgG1, IgG2, or IgG4 isotype shown in Table 5. In some embodiments, the HuPTM fusion protein comprises a sequence that is an Fc polypeptide or a variant of an Fc polypeptide sequence from Table 5, and the sequence is modified using one or more of the techniques described in Section 5.2.8 below to alter the effector function of the Fc polypeptide.
[0096] The recombinant AAV construct expresses the HuPTM anti-TNFα Fc fusion protein in cells, cell cultures, or subjects. The nucleotide sequence encoding the anti-TNFα Fc fusion protein may be a codon optimized for expression in human cells, and the incidence of CpG dimers in the sequence may be reduced to promote expression in human cells. In preferred embodiments, the transgene encodes one of the therapeutic anti-TNFα Fc fusion proteins disclosed herein, for example, the therapeutic anti-TNFα Fc fusion protein etanercept or EYS606 shown in Figures 2A and 2B herein, and in certain embodiments includes the relevant Fc domain provided in Table 6 or, alternatively, in Table 5. The Fc domain is discussed further in Section 5.2.8. Exemplary Fc domain sequences are provided in Table 6, and in Figures 3 and 5. Figure 2A provides the amino acid sequence of TNFR2:Fc fusion etanercept, and Figure 2B provides the amino acid sequence of TNFR1:Fc fusion EYS606 (see also Table 6).
[0097] In some embodiments, the transgene for the expression of the anti-TNFα Fc fusion protein may include a nucleotide sequence encoding the soluble extracellular portion of the human TNFα receptor type I (TNFR1) or type II (TNFR2), covalently bonded, for example, via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain as further described herein. In some embodiments, TNFR1 is fused to the Fc domain via a thrombin cleavage site (SEQ ID NO: 8).
[0098] Table 7 provides nucleotide sequences encoding the soluble extracellular domain of TNFR1 or TNFR2, optionally, the thrombin cleavage site, hinge region, and IgG1 Fc chain (CH2+CH3) of the therapeutic anti-TNFα Fc fusion protein disclosed herein. In certain embodiments, these nucleotide sequences are codons optimized for expression in human cells. See, for example, the etanercept codon-optimized sequences (SEQ ID NOs. 15-18) in Table 7.
[0099] The introduced gene may include a hinge region that forms an interchain disulfide bond (for example, a region containing the sequence CPPCPA (SEQ ID NO: 153)). An Fc domain sequence that does not contain the hinge region containing the sequence CCPCPA (SEQ ID NO: 153) does not form an intrachain disulfide bond, while an Fc fusion domain sequence having a portion of the hinge region at its C-terminus containing the sequence CPPCPA (SEQ ID NO: 153) forms an intrachain disulfide bond and, therefore, forms a dimeric fusion protein fragment. In some embodiments, the hinge contains all or part of the amino acid sequence EPKSCDKTHTCPPCPAPELLGG (SEQ ID NO: 145), and in particular EPKSCDKTHL (SEQ ID NO: 146), EPKSCDKTHT (SEQ ID NO: 147), EPKSCDKTHTCPPCPA (SEQ ID NO: 148), EPKSCDKTHLCPPCPA (SEQ ID NO: 149), DKTHTCPPCPAPELLGG (SEQ ID NO: 21), DKTHTCPPCPAPELLGGPSVFL (SEQ ID NO: 152), EPKSCDKTHTCPPCPAPELLGGPSVFL (SEQ ID NO: 150), or EPKSCDKTHLCPPCPAPELLGGPSVFL (SEQ ID NO: 151).
[0100] In certain embodiments, the viral vector provided herein comprises the following elements in the following order: a) a constitutive or inducible (e.g., hypoxia-inducible or rifamycin-inducible) promoter sequence, or a tissue-specific promoter / regulatory region, e.g., one of the regulatory regions provided in Table 1 or Table 1a, particularly a promoter that promotes ocular tissue-specific expression; and b) a sequence encoding a transgene (e.g., an anti-TNFα Fc fusion protein). In certain embodiments, the sequence containing the transgene encodes an anti-TNFα Fc fusion protein comprising a polypeptide containing the Fc domain of an immunoglobulin heavy chain, covalently bonded, for example, to a soluble extracellular component of a human TNFα receptor type I (TNFR1) or type II (TNFR2) via a peptide bond. In certain embodiments, the sequence containing the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that directs secretion and post-translational modification in the human ocular cells. In other embodiments, the sequence encodes a transgene product having the amino acid sequence of SEQ ID NOs: 10, 11, or 12. In preferred embodiments, the anti-TNFα fusion protein is etanercept or EYS606.
[0101] In certain embodiments, the viral vector provided herein comprises the following elements in the following order: a) a constitutive or inducible promoter sequence or tissue-specific promoter from, for example, one of the promoter or regulatory regions of Tables 1 and 1a; and b) a sequence encoding a transgene (e.g., an anti-TNFα Fc fusion protein) (the transgene comprises a signal peptide, a soluble extracellular component of TNFα receptor type I (TNFR1) or type II (TNFR2), covalently bonded, for example, via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain in order to form an anti-TNFα Fc fusion protein). In other embodiments, the viral vector provided herein comprises the following elements in the following order: a) an eye tissue-specific promoter listed in Tables 1 and 1a, and b) a sequence encoding a transgene containing a signal peptide (the transgene comprises a signal peptide, a soluble extracellular component of human TNFα receptor type I (TNFR1) or type II (TNFR2), covalently bonded, for example, via a peptide bond to a polypeptide containing the Fc domain of an immunoglobulin heavy chain to form an anti-TNFα Fc fusion protein). In certain embodiments, the viral vector provided herein further comprises a thrombin cleavage site linked to the C-terminus of a TNFR domain having the amino acid sequence LSPRGS (SEQ ID NO: 158).
[0102] In certain embodiments, an AAV vector is provided that includes an artificial genome comprising a viral capsid (see Figure 3) which is at least 95% identical in amino acid sequence to the AAV2.7m8 capsid, AAV8 capsid, AAV3B capsid, or AAVrh73 capsid, and an expression cassette adjacent to the AAV reverse terminal repeat (ITR) (the expression cassette contains a transgene encoding an anti-TNFα Fc fusion protein, which is operably linked to one or more regulatory sequences that control the expression of the transgene in one or more eye tissues).
[0103] rAAV vectors encoding and expressing therapeutic fusion proteins can be administered to treat, prevent, or improve symptoms of diseases or conditions suitable for treatment, prevention, or improvement of symptoms by the therapeutic fusion protein. Methods for expressing the HuPTM anti-TNFα Fc fusion protein in human cells using rAAV vectors and encoding constructs are also provided.
[0104] 5.2.8 Fc region modification In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein that associates to form a dimeric Fc fusion protein. Therefore, the transgene comprises a nucleotide sequence encoding a soluble extracellular portion of human TNFα receptor type I (TNFR1) or type II (TNFR2), covalently bonded, for example, via peptide bonds, to a polypeptide containing the Fc domain of an immunoglobulin heavy chain (Figures 2A and 2B), including, for example, all or part of the hinge region of the heavy chain and the N-terminus of the Fc domain peptide. Table 6 provides amino acid sequences of Fc polypeptides for specific therapeutic anti-TNFα Fc fusion proteins described herein. Alternatively, the sequences of IgG2 or IgG4 Fc domains, provided in Figure 4 and Table 5, may be utilized. As detailed herein, the transgene may include a nucleotide sequence encoding the Fc domain polypeptide of a therapeutic anti-TNFα Fc fusion protein, ligated at the N-terminus of the hinge region provided herein to a nucleotide sequence encoding the soluble extracellular portion of human TNFR (along with the amino acid sequences provided in Figures 2A and 2B and Table 6).
[0105] The term “Fc region” refers to a dimer of two “Fc polypeptides” (or “Fc domains”), each “Fc polypeptide” containing the heavy chain constant region of an antibody excluding the first constant region immunoglobulin domain. In some embodiments, the “Fc region” contains two Fc polypeptides linked by one or more disulfide bonds, chemical linkers, or peptide linkers. The “Fc polypeptide” refers to at least the last two constant region immunoglobulin domains of IgA, IgD, and IgG, or the last three constant region immunoglobulin domains of IgE and IgM, and may also include some or all of the flexible hinge N-terminus to these domains. For IgG, for example, the “Fc polypeptide” may include the immunoglobulin domains Cgamma2 (Cγ2, often referred to as the CH2 domain) and Cgamma3 (Cγ3, also referred to as the CH3 domain), and may include the lower part of the hinge domain between Cgamma1 (Cγ1, also referred to as the CH1 domain) and the CH2 domain. While the boundaries of Fc polypeptides can vary, human IgG heavy chain Fc polypeptides are typically defined as beginning at T223, C226, or P230 and containing residues up to their carboxyl terminus, with numbering following the EU index as found in Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Services, Springfield, Va.). In the case of IgA, for example, the Fc polypeptide may contain the immunoglobulin domains C alpha 2 (Cα2) and C alpha 3 (Cα3) and may include the lower part of the hinge between C alpha 1 (Cα1) and Cα2.
[0106] In certain embodiments, the Fc polypeptide is the Fc polypeptide of etanercept or EYS606 (see Table 6). In other embodiments, the Fc polypeptide is the IgG Fc polypeptide. The Fc polypeptide may be derived from, for example, the IgG1, IgG2, or IgG4 isotype (see Figure 4 for alignments of IgG1, IgG2, and IgG4 Fc domain sequences), or it may be the IgG3 Fc domain, depending on the desired effector activity of the therapeutic antibody. In some embodiments, the manipulated heavy chain constant region (CH) containing the Fc domain is chimeric. Thus, the chimeric CH region combines CH domains derived from two or more immunoglobulin isotypes and / or subtypes. For example, the chimeric (or hybrid) CH region contains some or all of the Fc domains from IgG, IgA, and / or IgM. In other embodiments, the chimeric CH region includes some or all of the CH2 domains derived from human IgG1, human IgG2, or human IgG4 molecules, combined with some or all of the CH3 domains derived from human IgG1, human IgG2, or human IgG4 molecules. In other embodiments, the chimeric CH region includes a chimeric hinge region. [Table 6]
[0107] In some embodiments, the recombinant vector encodes a therapeutic Fc fusion containing an engineered (mutant) Fc region, e.g., an engineered Fc region of the IgG constant region. Modifications to the antibody constant region, Fc region, or Fc fragment of an IgG antibody can alter one or more effector functions, such as Fc receptor binding or neonatal Fc receptor (FcRn) binding, and therefore half-life, CDC activity, ADCC activity, and / or ADPC activity, compared to a wild-type IgG constant region without the listed modifications, or a corresponding antibody having an IgG heavy chain constant region. Therefore, in some embodiments, the antibody can be engineered to provide an antibody constant region, Fc region, or Fc fragment of an IgG antibody that exhibits modified binding (compared to a reference or wild-type constant region without the listed modifications) to one or more Fc receptors (e.g., FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, FcγRIIIB, FcγRIV, or FcRn receptors). In some embodiments, the antibody, antibody constant region, Fc region, or Fc fragment of an IgG antibody exhibiting one or more modified effector functions, such as CDC, ADCC, or ADCP activity, compared to a corresponding antibody having a wild-type IgG constant region, or IgG constant without the listed modifications (may be multiple).
[0108] "Effector function" refers to biochemical events resulting from the interaction between the antibody Fc region and the Fc receptor or ligand. Examples of effector functions include FcγR-mediated effector functions such as ADCC and ADCP, as well as complement-mediated effector functions such as CDC.
[0109] "Effector cells" refer to immune system cells that express one or more Fc receptors and mediate one or more effector functions. Effector cells include, but are not limited to, monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, macrogranular lymphocytes, Langerhans cells, natural killer (NK) cells, and T cells, and may originate from any organism, including, but are not limited to, humans, mice, rats, rabbits, and monkeys.
[0110] "ADCC," or "antibody-dependent cell-mediated cytotoxicity," refers to a cell-mediated reaction in which nonspecific cytotoxic effector (immune) cells expressing FcγR recognize antibodies bound to target cells, subsequently causing lysis of the target cells.
[0111] "ADCP," or "antibody-dependent cell-mediated phagocytosis," refers to a cell-mediated response in which nonspecific cytotoxic effector (immune) cells expressing FcR recognize antibodies bound to target cells, subsequently triggering phagocytosis of those target cells.
[0112] "CDC," or "complement-dependent cell injury," refers to a reaction in which one or more complement protein components recognize antibodies bound to target cells, subsequently causing the target cells to lyse.
[0113] In some embodiments, modifications of the Fc domain include, but are not limited to, the following modifications and their combinations, with reference to the EU numbering of the IgG constant region (see Figure 4): 233, 234, 235, 236, 237, 238, 239, 248, 249, 250, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 297, 298, 3 01, 303, 305, 307, 308, 309, 311, 312, 315, 318, 320, 322, 324, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 337, 338, 339, 340, 342, 344, 356, 358, 359, 360, 361, 362, 373, 375, 376, 378, 380, 382, 383, 384, 386, 388, 389, 398, 414, 416, 419, 428, 430, 433, 434, 435, 437, 438, and 439.
[0114] In certain embodiments, the Fc region includes the addition, deletion, or substitution of one or more amino acids from IgG amino acid residues 251-256, 285-290, 308-314, 385-389, and 428-436. In some embodiments, 251-256, 285-290, 308-314, 385-389, and 428-436 (Kabat's EU numbering, see Figure 4) are substituted with histidine, arginine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, or glutamine. In some embodiments, non-histidine residues are substituted with histidine residues. In some embodiments, histidine residues are substituted with non-histidine residues.
[0115] Enhanced FcRn binding by antibodies with manipulated Fc results in preferential binding of the affinity-enhanced antibody to FcRn compared to antibodies with wild-type Fc, thus resulting in a net enhanced recycling of the FcRn affinity-enhanced antibody, which further increases the antibody half-life. The enhanced recycling approach enables highly effective targeting and clearance of antigens, including "high-titer" circulating antigens such as C5, cytokines, or bacterial or viral antigens.
[0116] In certain embodiments, a modified constant region, Fc region, or Fc fragment of an IgG antibody is provided that has enhanced binding to FcRn in serum compared to a wild-type Fc region (without the manipulated modification). In some cases, an antibody, e.g., an IgG antibody, is manipulated to bind to FcRn at a neutral pH, e.g., pH 7.4 or higher, thereby enhancing the pH dependence of binding to FcRn compared to a wild-type Fc region (without the manipulated modification). In some cases, an antibody, e.g., an IgG antibody, is manipulated to enhance binding to FcRn in endosomes (e.g., increased affinity or K) compared to the binding of wild-type IgG and / or a reference antibody to FcRn at acidic pH, and compared to binding to FcRn in serum (e.g., at a neutral pH, e.g., pH 7.4 or higher). DThe modified antibody constant region, Fc region, or Fc fragment of an IgG antibody is provided that exhibits an improved serum or resident tissue half-life compared to a corresponding antibody having a wild-type IgG constant region or an IgG constant without the listed modifications(s).
[0117] Non-restrictive examples of such Fc modifications include, for example, modifications at position 250 (e.g., E or Q), positions 250 and 428 (e.g., L or F), position 252 (e.g., LN / Y / W or T), position 254 (e.g., S or T), and position 256 (e.g., S / R / Q / E / D or T), or modifications at position 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or position 434 (e.g., H / F or Y), or modifications at position 250 and / or 428, or modifications at position 307 or 308 (e.g., 308F, V308F), and position 434. In one embodiment, the modifications include modifications of 428L (e.g., M428L) and 434S (e.g., N434S); modifications of 428L, 259l (e.g., V259l), and 308F (e.g., V308F); modifications of 433K (e.g., H433K) and 434 (e.g., 434Y); modifications of 252, 254, and 256 (e.g., 252Y, 254T, and 256E); modifications of 250Q and 428L (e.g., T250Q and M428L); and modifications of 307 and / or 308 (e.g., 308F or 308P) (EU numbering, see Figure 4).
[0118] In some embodiments, the Fc region may be a mutant type such as hIgG1 Fc containing the M252 mutation, for example, M252Y, S254T, and T256E ("YTE mutations") enhance affinity for human FcRn (Dall'Acqua, et al., 2002, J Immunol 169:5171-5180) and result in the subsequent crystal structure of this mutant antibody bound to hFcRn, leading to the formation of two salt crosslinks (Oganesyan, et al. 2014, JBC 289(11):7812-7824). Antibodies with YTE mutations have been administered to monkeys and humans, and their pharmacokinetic properties have been significantly improved (Haraya, et al., 2019, Drug Metabolism and Pharmacokinetics, 34(1):25-41).
[0119] In some embodiments, modification of one or more amino acid residues in the Fc region may reduce the half-life in systemic circulation (serum), but improve retention in tissues (e.g., eyes) by disabling FcRn binding (e.g., H435A, EU numbering by Kabat) (Ding et al., 2017, MAbs 9:269-284, and Kim, 1999, Eur J Immunol 29:2819).
[0120] In some embodiments, the Fc domain may be manipulated to activate all or part of the normal Fc effector function, or to deactivate it entirely, without affecting the desired pharmacokinetic properties of the Fc polypeptide (e.g., an antibody). Fc polypeptides with modified effector function may be desirable because they can reduce undesirable side effects such as activation of effector cells by the therapeutic protein.
[0121] Methods for modifying or even ablating effector function may include mutations or modifications of amino acid residues in the hinge region of an antibody. For example, according to the EU numbering system, IgG Fc domain variants containing 234A, 237A, and 238S substitutions exhibit reduced complement-dependent lysis and / or cell-mediated disruption. Deletions and / or substitutions in the lower hinge, such as deletions or modifications to glycine at positions 233–236 within the hinge domain (EU numbering), have been shown in the art to significantly reduce ADCC and CDC activity.
[0122] In certain embodiments, the Fc domain is an aglycosylated Fc domain having a substitution at residue 297 or 299 to modify the glycosylation site at 297 so that the Fc domain is not glycosylated. Such an aglycosylated Fc domain may have reduced ADCC or other effector activity.
[0123] Non-limiting examples of proteins containing mutants and / or chimeric CH regions having modified effector functions, as well as methods for manipulating and testing mutant antibodies, are described in the art, for example, KLAmour, et al., Eur. J. Immunol. 1999, 29:2613-2624, Lazar et al., Proc. Natl. Acad. Sci. USA 2006, 103:4005, U.S. Patent Application Publication 2007 / 0135620A1 published on 14 June 2007, U.S. Patent Application Publication 2008 / 0154025A1 published on 26 June 2008, U.S. Patent Application Publication 2010 / 0234572A1 published on 16 September 2010, U.S. Patent Application Publication 2012 / 0225058A1 published on 6 September 2012, 2 These are described in U.S. Patent Application Publication No. 2015 / 0337053A1, published on November 26, 2015; International Publication No. WO20 / 16161010A2, published on October 6, 2016; U.S. Patent No. 9,359,437, issued on June 7, 2016; and U.S. Patent No. 10,053,517, issued on August 21, 2018 (all of which are incorporated herein by reference).
[0124] The C-terminal lysine (-K), which is conserved in the heavy chain genes of all human IgG subclasses, is generally absent in antibodies circulating in serum. The C-terminal lysine is cleaved in circulation, resulting in heterogeneous populations of circulating IgG (van den Bremer et al., 2015, mAbs 7:672-680). By deleting the DNA encoding the C-terminal lysine (-K) or glycine-lysine (-GK) at the Fc terminus of a full-length mAb vectorization construct, more homogeneous antibody products can be produced in situ (see Hu et al., 2017 Biotechnol. Prog. 33:786-794 (the entire article is incorporated herein by reference)).
[0125] 5.2.9 Manufacturing and testing of vectors The viral vectors provided herein may be produced using host cells. The viral vectors provided herein may be produced using mammalian host cells, such as A549, WEHI, 10T1 / 2, BHK, MDCK, COS1, COS7, BSC1, BSC40, BMT10, VERO, W138, HeLa, 293, Saos, C2C12, L, HT1080, HepG2, primary fibroblasts, hepatocytes, and myoblasts. The viral vectors provided herein may be produced using host cells from humans, monkeys, mice, rats, rabbits, or hamsters.
[0126] Host cells are stably transformed using the transgene and associated elements (e.g., vector genome), as well as means for producing the virus in the host cells, such as sequences encoding replication and capsid genes (e.g., the rep and cap genes of AAV). For a method of producing a recombinant AAV vector with the AAV8 capsid, see Section IV of the Embodiments for Carrying Out the Invention of U.S. Patent No. 7,282,199 B2 (which is incorporated herein by reference in its entirety). The genomic copy titer of the vector can be determined, for example, by TAQMAN® analysis. Virons can be recovered, for example, by CsCl2 precipitation.
[0127] Alternatively, baculovirus expression systems in insect cells can be used to produce AAV vectors. For a review, see Aponte-Ubillus et al., 2018, Appl. Microbiol. Biotechnol. 102:1045-1054 (the entire text on the manufacturing technique is incorporated herein by reference).
[0128] Transgene expression from the vectors described herein can be measured using in vitro assays, such as cell culture assays, and thus the efficacy of the vectors can be demonstrated. For example, transgene expression can be evaluated using the PER.C6® cell line (Lonza), a cell line derived from human embryonic retinal cells, or retinal pigment epithelial cells, such as the retinal pigment epithelial cell line hTERT RPE-1 (available from ATCC®). Once expressed, the characteristics of the expressed product can be determined, including the determination of the glycosylation and tyrosine sulfate patterns associated with the human glycosylated anti-TNFα Fc fusion protein. Glycosylation patterns and methods for determining them are discussed in Section 5.4. In addition, the benefits arising from the glycosylation / sulfation of cell-expressed human glycosylated anti-TNFα Fc fusion protein can be determined using assays known in the art, such as those described in Section 5.4.
[0129] Vector genome concentration (GC) or vector genome copy can be evaluated using digital PCR (dPCR) or ddPCR® (BioRad Technologies, Hercules, CA, USA). In one example, ocular tissue samples, such as aqueous humor and / or vitreous humor samples, are obtained at several time points. In another example, several mice are sacrificed at various time points after injection. Ocular tissue samples are subjected to total DNA extraction and dPCR assays for vector copy number. The number of vector genome (transgene) copies per gram of tissue may be measured in a single biopsy sample or in various tissue sections at consecutive time points to reveal the extent of AAV throughout the eye. Total DNA from the collected ocular fluid or tissue is extracted using the DNeasy Blood & Tissue Kit and DNA concentration measured using a Nanodrop spectrophotometer. Digital PCR is performed using a Naica Crystal Digital PCR system (Stilla Technologies) to determine the vector copy number for each tissue sample. A two-color multiplexing system is applied to simultaneously measure the transgene AAV and endogenous control gene. In short, the transgene probe can be labeled with FAM (6-carboxyfluorescein) dye, while the endogenous control probe can be labeled with VIC fluorescent dye. The number of delivered vector copies per diploid cell in a particular tissue section is calculated as follows: (number of vector copies) / (endogenous control) × 2. Over time, vector copies in specific cell types or tissues such as cornea, iris, ciliary body, Schlemm's canal cells, trabecular meshwork, retinal cells, RPE cells, RPE choroidal tissue, or optic nerve cells may indicate sustained expression of the transgene by the tissue.
[0130] 2.9 Composition Pharmaceutical compositions suitable for administration to human subjects include a suspension of a recombinant vector in a formulation buffer comprising a physiologically compatible aqueous buffer, a surfactant, and an optional excipient. Such a formulation buffer may contain one or more of the following: polysaccharides, surfactants, polymers, or oils. In some embodiments, the pharmaceutical composition comprises rAAV combined with a pharmaceutically acceptable carrier for administration to a subject. In one embodiment, the term “pharmaceutically acceptable” means approved by a federal or state regulatory authority for use in animals, more specifically in humans, or listed in the United States Pharmacopeia or other commonly recognized pharmacopoeias. The term “carrier” refers to a diluent, adjuvant (e.g., Freund’s complete and incomplete adjuvants), excipient, or vehicle administered with the drug. Such pharmaceutical carriers may be sterile liquids such as water and oil, including petroleum, animal, plant, or synthetic origins, including, for example, peanut oil, soybean oil, mineral oil, and sesame oil. Water is a common carrier when the pharmaceutical composition is administered intravenously. Physiological saline and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, and ethanol.Further examples of pharmaceutically acceptable carriers, excipients, and stabilizers include buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid; low molecular weight polypeptides; proteins such as serum albumin and gelatin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, salt-forming counterions such as sodium; and / or nonionic surfactants known in the art, such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®. The pharmaceutical compositions of the present invention may also contain, in addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, and preservatives. These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like.
[0131] 3. How to treat non-infectious uveitis In another embodiment, the present invention provides a method for treating subjects in need of treatment for non-infectious uveitis or other indications treatable with anti-TNFα Fc fusion proteins, the method comprising administering recombinant AAV particles comprising an expression cassette encoding an anti-TNFα Fc fusion protein and its variants. Subjects in need of treatment include subjects with or predisposed to non-infectious uveitis, e.g., subjects at risk of developing or relapsing non-infectious uveitis or other indications treatable with anti-TNFα Fc fusion proteins. Subjects to whom such gene therapy is administered may be responsive to anti-TNFα, e.g., etanercept, adalimumab, infliximab, or golimumab. In certain embodiments, the method encompasses treating patients diagnosed with non-infectious uveitis who, in certain embodiments, are identified as responsive to treatment with anti-TNFα Fc fusion proteins or are considered good candidates for therapy with anti-TNFα Fc fusion proteins. In certain embodiments, the patient has been previously treated with an anti-TNFα Fc fusion protein. To determine the response, the anti-TNFα Fc fusion protein (e.g., produced in human cell cultures, bioreactors, etc.) can be directly administered to the target.
[0132] In certain embodiments, the present invention provides a method for treating a human subject in need of treatment for non-infectious uveitis or other indications suitable for treatment with an anti-TNFα Fc fusion protein, comprising administering a therapeutically effective amount of a recombinant nucleotide expression vector containing a transgene encoding an anti-TNFα Fc fusion protein, an Fc region operably linked to one or more regulatory sequences controlling the expression of the transgene in human eye tissue cells, to the eye (or liver and / or muscle) of the subject, thereby forming a depot that releases a HuPTM form of the mAb or its antigen-binding fragment. Subretinal, intravitreous, anterior chamber, or choroidal administration should result in the expression of the soluble transgene product in one or more of the following retinal cell types: human photoreceptor cells (cone cells, rod cells); horizontal cells; bipolar cells; amarcline cells; retinal ganglion cells (midget cells, parasol cells, bilaminated cells, giant retinal ganglion cells, photosensitive ganglion cells, and Müller glia); as well as retinal pigment epithelial cells or other ocular tissue cells: corneal cells, iris cells, ciliary cells, Schlemm's canal cells, trabecular meshwork cells, RPE-colloid tissue cells, or optic nerve cells.
[0133] Recombinant vectors and pharmaceutical compositions for treating diseases or disorders in subjects requiring such treatment are described in Section 5.2. Such vectors should be tropic to human eye tissue or liver and / or muscle cells and may include those carrying non-replicating rAAVs, particularly AAV2.7m8, AAV3B, AAV8, AAAV9, AAV10, AAVrh10, or AAVrh73 capsids. Recombinant vectors may be administered in any manner, for example, by introducing the recombinant vector into the eye, so that the recombinant vector enters the ocular tissue cells. Such vectors should further contain one or more regulatory sequences that control the expression of the transgene in human eye tissue cells and / or human liver and muscle cells, including, but not limited to, human rhodopsin kinase (GRK1) promoters (SEQ ID NO: 54 or 117), mouse pyramidal arrestin (CAR) promoters (SEQ ID NOs: 114-116), human red opsin (RedO) promoters (SEQ ID NO: 112), or Best1 / GRK promoters (SEQ ID NO: 161) (see also Tables 1 and 1a).
[0134] 5.4 N-glycosylation, tyrosine sulfated, and O-glycosylation The amino acid sequences (primary sequences) of the HuPTM anti-TNFα Fc fusion proteins disclosed herein each include at least one site within the amino acid sequence of the Fc fusion protein where N-glycosylation or O-glycosylation occurs (see Figures 2A and 2B). Post-translational modifications also occur in the Fc domain of the full-length antibody, particularly at residue N297 (by EU numbering, see Figure 4).
[0135] Alternatively, mutations can be introduced into the Fc domain to modify the glycosylation site of residue N297 (EU numbering, see Figure 4), specifically by substituting asparagine at 297 or threonine at 299 with another amino acid to remove the glycosylation site and result in a non-glycosylated Fc domain.
[0136] 5.4.1 N-glycosylation Reverse glycosylation site The canonical N-glycosylation sequence is known in the art to be Asn-X-Ser(or Thr), where X can be any amino acid except Pro. However, it has recently been demonstrated that asparagine (Asn) residues in human antibodies can be glycosylated in the context of the reverse consensus motif Ser(or Thr)-X-Asn, where X can be any amino acid except Pro. See Valliere-Douglass et al., 2009, J. Biol. Chem. 284:32493-32506 and Valliere-Douglass et al., 2010, J. Biol. Chem. 285:16012-16022. As disclosed herein, certain anti-TNFα Fc fusion proteins disclosed herein include canonical and / or reverse consensus sequences.
[0137] Non-consensus glycosylated sites In addition to reverse N-glycosylation sites, it has recently been demonstrated that glutamine (Gln) residues in human antibodies can be glycosylated in the context of the non-consensus motif Gln-Gly-Thr. See Valliere-Douglass et al., 2010, J. Biol. Chem. 285:16012-16022. Surprisingly, certain HuGlyFab fragments disclosed herein contain such non-consensus sequences. Furthermore, O-glycosylation involves the enzymatic addition of N-acetylgalactosamine to serine or threonine residues. It has been demonstrated that amino acid residues present in the hinge region of antibodies can be O-glycosylated. The potential for O-glycosylation confers another advantage to the therapeutic anti-TNFα Fc fusion protein provided herein compared to, for example, antigen-binding fragments produced in E. coli, also because E. coli does not naturally possess a mechanism equivalent to that used in human O-glycosylation. (Instead, O-glycosylation in E. coli has only been demonstrated when the bacterium is modified to contain a specific O-glycosylation mechanism. See, for example, Farid-Moayer et al., 2007, J. Bacteriol. 189:8088-8098.)
[0138] Manipulated N-glycosylation sites In certain embodiments, the nucleic acid encoding the anti-TNFα Fc fusion protein is modified to include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more N-glycosylation sites (including canonical N-glycosylation consensus sequences, reverse N-glycosylation sites, and non-consensus N-glycosylation sites) than typically associated with the HuPTM anti-TNFα Fc fusion protein (e.g., compared to the number of N-glycosylation sites that associate with the HuPTM anti-TNFα Fc fusion protein in its unmodified state). In certain embodiments, the introduction of glycosylation sites is achieved by inserting N-glycosylation sites (including canonical N-glycosylation consensus sequences, reverse N-glycosylation sites, and non-consensus N-glycosylation sites) at various points within the primary structure of the antigen-binding fragment, but such introduction does not affect the binding of the antibody or antigen-binding fragment to that antigen. The introduction of a glycosylation site can be achieved, for example, by adding a new amino acid to the primary structure of a soluble extracellular TNFR-domain or Fc domain to generate an N-glycosylation site (e.g., completely or partially adding a glycosylation site), or by mutating an existing amino acid within the soluble extracellular TNFR-domain or Fc domain (e.g., no amino acid is added, but selected amino acids in the anti-TNFα Fc fusion protein are mutated to form an N-glycosylation site). Those skilled in the art will recognize that the amino acid sequence of a protein can be readily modified using approaches known in the art, such as recombinant approaches involving modification of the protein-coding nucleic acid sequence.
[0139] In certain embodiments, the anti-TNFα Fc fusion protein is modified so that it can be hyperglycosylated when expressed in mammalian cells such as retina, CNS, liver, or muscle cells.
[0140] N-glycosylation of HuPTM anti-TNFα Fc fusion protein Unlike small molecule drugs, biological agents typically contain a mixture of many variants with different modifications or forms that may have different potency, pharmacokinetics, and / or safety profiles. It is not essential that all molecules produced by either gene therapy or protein therapy approaches be fully glycosylated and sulfated. Rather, the population of glycoproteins produced should have sufficient glycosylation (including 2,6-sialylation) and sulfatedness to demonstrate efficacy. The goals of gene therapy treatments provided herein may, for example, be to slow or halt the progression of a disease or abnormal condition, or to reduce the severity of one or more symptoms associated with a disease or abnormal condition.
[0141] When the HuPTM anti-TNFα Fc fusion protein is expressed in human cells, the N-glycosylation site of the Fc fusion protein can be glycosylated with various different glycans. The glycosylation of the Fc domain is characterized by a single N-linked glycan at asparagine 297 (EU numbering, see Figure 4). The glycan plays an essential structural and functional role in influencing antibody effector functions, such as binding to the Fc receptor (see, for example, Jennewein and Alter, 2017, Trends In Immunology 38:358, for a discussion of the role of Fc glycosylation in antibody function). Removal of the Fc region glycan almost completely eliminates the effector function (Jennewein and Alter, 362). The composition of Fc glycans has been shown to affect effector function; for example, reduced galactosylation and fucosylation have been shown to increase ADCC activity, while sialylation correlates with anti-inflammatory effects (ibid., 364). Disease status, genetics, and even diet may influence the composition of Fc glycans in vivo. For recombinant expression antibodies and Fc fusion proteins, the glycan composition can vary significantly depending on the type of host cell used for recombinant expression, and strategies are available to control and modify the glycan composition in therapeutic antibodies recombinantly expressed in cell cultures such as CHO to alter effector function (see, for example, US2014 / 0193404 by Hansen et al.). Therefore, the HuPTM anti-TNFα Fc fusion protein provided herein may advantageously have glycans at N297 that are closer to the natural human glycan composition than antibodies expressed in non-human host cells.
[0142] Importantly, when the HuPTM anti-TNFα Fc fusion protein is expressed in human cells, the need for in vitro production in prokaryotic host cells (e.g., E. coli) or eukaryotic host cells (e.g., CHO cells or NS0 cells) is avoided. Instead, as a result of the method described herein, the N-glycosylation site of the HuPTM anti-TNFα Fc fusion protein is advantageously decorated with glycans relevant to and beneficial for human therapy. These advantages are, for example, that CHO cells (1) do not express 2,6-sialyltransferase and therefore cannot be supplemented with 2,6-sialic acid during N-glycosylation, (2) Neu5Gc can be supplemented with sialic acid instead of Neu5Ac, (3) they can also produce immunogenic glycans and α-Gal antigens that react with anti-α-Gal antibodies present in most individuals and can cause anaphylaxis at high concentrations, and (4) E. coli does not naturally contain the components necessary for N-glycosylation, making it impossible to achieve when used for antibody / antigen binding fragment production.
[0143] Assays for determining the glycosylation pattern of anti-TNFα Fc fusion proteins are known in the art. For example, glycans can be analyzed using hydrazine degradation. First, polysaccharides are released from their associated proteins by incubation with hydrazine (the Ludger Liberate Hydrazine Degradation Glycan Release Kit (Oxfordshire, UK) can be used). Nucleophilic hydrazine attacks the glycosidic bond between the polysaccharide and the carrier protein, allowing for the release of the attached glycan. The N-acetyl group is lost during this procedure and needs to be reconstituted by re-N-acetylation. The glycan may also be released using enzymes such as glycosidases or endoglycosidases such as PNGase F and Endo H, which are cleaved more cleanly and have fewer side effects than hydrazine. The free glycan can be purified on a carbon column and subsequently labeled at the reducing end with fluorophor 2-aminobenzamide. Labeled polysaccharides can be separated on a GlycoSep-N column (GL Sciences) according to the HPLC protocol of Royle et al, Anal Biochem 2002, 304(1):70-90. The resulting fluorescence chromatogram shows the length and number of repeating units of the polysaccharide. Structural information can be collected by collecting individual peaks and subsequently performing MS / MS analysis. This allows for the confirmation of the monosaccharide composition and sequence of the repeating units, and additionally, the homogeneity of the polysaccharide composition can be identified. Specific peaks of low or high molecular weight molecules can be analyzed by MALDI-MS / MS, and the results are used to confirm the glycan sequence. Each peak in the chromatogram corresponds to a polymer consisting of a certain number of repeating units and their fragments, e.g., sugar residues, e.g., glycans. Therefore, the chromatogram allows for the measurement of the length distribution of polymers, e.g., glycans. Elution time is an indicator of polymer length, while fluorescence intensity correlates with the molar abundance of each polymer, e.g., glycan.Another method for evaluating glycans associated with anti-TNFα Fc fusion proteins is described in Montacir et al., 2018, The Protein Journal, 37(2), 164-179.
[0144] The uniformity or heterogeneity of the glycan pattern associated with anti-TNFα Fc fusion proteins is related to both the length or size of the glycans and the number of glycans present at the glycosylation sites, and can therefore be assessed using methods known in the art, such as methods for measuring the length or size and hydrodynamic radius of glycans. HPLC, including size exclusion, normal phase, reverse phase, and anion exchange HPLC, as well as capillary electrophoresis, allows for the measurement of hydrodynamic radius. The greater the number of glycosylation sites in a protein, the greater the variability in hydrodynamic radius compared to carriers with fewer glycosylation sites. However, when single glycan chains are analyzed, they may be more homogeneous due to their more controlled length. Glycan length can be measured by hydrazine degradation, SDS-PAGE, and capillary gel electrophoresis. In addition, homogeneity may also mean that the usage pattern of a particular glycosylation site varies over a wider / narrower range. These factors can be measured by glycopeptide LC-MS / MS.
[0145] In certain embodiments, the HuPTM anti-TNFα Fc fusion protein also does not contain detectable NeuGc and / or α-Gal. “Detectable NeuGc” or “Detectable α-Gal” or “Does not contain or have NeuGc or α-Gal” means, as used herein, that the HuPTM anti-TNFα Fc fusion protein does not contain a NeuGc or α-Gal moiety that is detectable by standard assay methods known in the art. For example, NeuGc can be detected by HPLC according to Hara et al., 1989, “Highly Sensitive Determination of N-Acetyl-and N-Glycolylneuraminic Acids in Human Serum and Urine and Rat Serum by Reversed-Phase Liquid Chromatography with Fluorescence Detection.” J.Chromatogr., B:Biomed. 377, 111-119 (a method for detecting NeuGc is incorporated herein by reference). Alternatively, NeuGc can be detected by mass spectrometry. α-Gal may be detected using ELISA (see, e.g., Galili et al., 1998, “A sensitive assay for measuring α-Gal epitope expression on cells by a monoclonal anti-Gal antibody.” Transplantation. 65(8):1129-32) or by mass spectrometry (see, e.g., Ayoub et al., 2013, “Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.” Landes Bioscience. 5(5):699-710).Furthermore, please refer to the references cited in Platts-Mills et al., 2015, “Anaphylaxis to the Carbohydrate Side-Chain Alpha-gal,” Immunol Allergy Clin North Am. 35(2):247-260.
[0146] Advantages of N-glycosylation N-glycosylation confers numerous benefits to the HuPTM anti-TNFα Fc fusion protein described herein. Since E. coli does not naturally possess the components necessary for N-glycosylation, such benefits cannot be achieved by the production of anti-TNFα Fc fusion proteins in E. coli. Furthermore, since CHO cells lack the components necessary for the addition of certain glycans (e.g., 2,6-sialic acid and bisected GlcNAc), and because either CHO or mouse cell lines add NN-glycolylneuraminic acid ("Neu5Gc" or "NeuGc"), which is not naturally occurring in humans (and potentially immunogenic), instead of the dominant human sialic acid, N-acetylneuraminic acid ("Neu5Ac"), some benefits cannot be achieved, for example, through antibody production in CHO cells (or mouse cells such as NS0 cells). See, for example, Dumont et al., 2015, Crit. Rev. Biotechnol. 36(6):1110-1122, Huang et al., 2006, Anal. Biochem. 349:197-207 (NeuGc is a dominant sialic acid in mouse cell lines such as SP2 / 0 and NS0), and Song et al., 2014, Anal. Chem. 86:5661-5666 (each of which is incorporated herein in whole by reference). Furthermore, CHO cells can also produce immunogenic glycans and α-Gal antigens that react with anti-α-Gal antibodies present in most individuals, which can cause anaphylaxis at high concentrations. See, for example, Bosques, 2010, Nat. Biotech. 28:1153-1156. The human glycosylation patterns of the HuPTM anti-TNFα Fc fusion protein described herein should reduce the immunogenicity of the transgene product and improve its efficacy.
[0147] Non-canonical glycosylation sites typically result in low levels of glycosylation (e.g., 1–5%) of the anti-TNFα Fc fusion protein population, but the functional benefits can be significant (see, e.g., van de Bovenkamp et al., 2016, J.Immunol. 196:1435–1441). For example, glycosylation can affect antibody stability, half-life, and binding properties. To determine the effect of anti-TNFα Fc fusion protein glycosylation on the affinity of the fusion protein to a target, any technique known to those skilled in the art, such as enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance (SPR), can be used. To determine the effect of glycosylation on the half-life of anti-TNFα Fc fusion proteins, any technique known to those skilled in the art can be used, for example, by measuring the radioactivity level in the blood or organs of a subject to which a radiolabeled antibody has been administered. To determine the effect of glycosylation on the stability of anti-TNFα Fc fusion proteins, for example, the level of aggregation or the level of protein spread, any technique known to those skilled in the art may be used, such as differential scanning calorimetry (DSC), high-performance liquid chromatography (HPLC), such as size exclusion high-performance liquid chromatography (SEC-HPLC), capillary electrophoresis, mass spectrometry, or turbidiometry.
[0148] The presence of sialic acid on the HuPTM anti-TNFα Fc fusion protein used in the method described herein may affect the clearance rate of the HuPTM anti-TNFα Fc fusion protein. Therefore, the sialic acid pattern of the HuPTM anti-TNFα Fc fusion protein can be used to generate therapeutic agents with optimized clearance rates. Methods for evaluating the clearance rate of anti-TNFα Fc fusion proteins are known in the art.
[0149] In another specific embodiment, the benefit handed down by N-glycosylation is reduced aggregation. The occupied N-glycosylation site can mask amino acid residues prone to aggregation, resulting in reduced aggregation. Such N-glycosylation sites may be native to the anti-TNFα Fc fusion protein used herein, or they may be engineered into the antigen-binding fragment used herein, resulting in a HuPTM anti-TNFα Fc fusion protein that is less prone to aggregation when expressed, for example, in human cells. Methods for evaluating antibody aggregation are known in the art. See, for example, Courtois et al., 2016, mAbs 8:99-112 (which is incorporated herein by reference in its entirety).
[0150] In another specific embodiment, the benefit confederated by N-glycosylation is reduced immunogenicity. Such N-glycosylation sites may be naturally occurring in the antigen-binding fragments used herein or may be engineered into the antigen-binding fragments used herein, resulting in a HuPTM anti-TNFα Fc fusion protein that, when expressed, for example, in human eye tissue cells, exhibits low immunogenicity.
[0151] In another specific embodiment, the benefit confederated by N-glycosylation is protein stability. N-glycosylation of proteins is well known to confer stability to them, and methods for evaluating the resulting protein stability are known in the art. See, for example, Sola and Griebenow, 2009, J Pharm Sci., 98(4):1223-1245.
[0152] In another specific embodiment, the benefit borne by N-glycosylation is modified binding affinity. Assays for measuring binding affinity are known in the art.
[0153] 5.4.2 O-glycosylation O-glycosylation involves the enzymatic addition of N-acetylgalactosamine to a serine or threonine residue. It has been demonstrated that amino acid residues present in the hinge region of anti-TNFα Fc fusion proteins can be O-glycosylated. In certain embodiments, the anti-TNFα Fc fusion protein comprises all or part of the hinge region and can therefore be O-glycosylated when expressed in human cells. The possibility of O-glycosylation confers another advantage to the anti-TNFα Fc fusion protein provided herein compared, for example, to the anti-TNFα Fc fusion protein produced in E. coli, also because E. coli does not naturally possess a mechanism equivalent to that used in human O-glycosylation. (Instead, O-glycosylation in E. coli has only been demonstrated when the bacterium is modified to contain a specific O-glycosylation mechanism. See, for example, Farid-Moayer et al., 2007, J. Bacteriol. 189:8088-8098.) O-glycosylated anti-TNFα Fc fusion proteins share advantageous features with N-glycosylated anti-TNFα Fc fusion proteins by possessing glycans (as discussed above).
[0154] 5.5 Vector HuP™ anti-TNFα Fc fusion protein construct and formulation for non-infectious uveitis Compositions and methods for the delivery of HuPTM anti-TNFα Fc fusion proteins, such as TNFR1:Fc fusion proteins or TNFR2:Fc fusion proteins, that bind to tumor necrosis factor alpha (TNFα), such as etanercept or EYS606 (Figures 2A and 2B), are described and shown to be used for the treatment of non-infectious uveitis. In certain embodiments, the HuPTM anti-TNFα Fc fusion protein has the amino acid sequence of etanercept or EYS606, or a biosimilar or biobetter thereof. The amino acid sequences of the human TNFα receptor type I (TNFR1) or type II (TNFR2) and the soluble extracellular portion of the Fc domain of the fusion protein are provided in Figures 2A and 2B and Table 6. Delivery may be achieved via gene therapy, for example, by administering a viral vector or other DNA expression construct encoding a therapeutic anti-TNFα Fc fusion protein (and / or its hyperglycosylated derivatives or other derivatives) to a patient (human subject) diagnosed with one or more symptoms of non-infectious uveitis to create a permanent depot that continuously supplies HuPTM, e.g., a human glycosylated transgene product, to ocular tissue.
[0155] Transgene A recombinant vector is provided that contains a transgene encoding a HuPTM anti-TNFα Fc fusion protein that binds to TNFα, and that can be administered to deliver the HuPTM anti-TNFα Fc fusion protein to a patient. The transgene is a nucleic acid containing a soluble extracellular component of a human TNFα receptor type I (TNFR1) or type II (TNFR2), such as etanercept or EYS606, as well as a nucleotide sequence encoding an anti-TNFα Fc fusion protein containing an Fc domain, or a variant thereof as detailed herein. The transgene may also encode an anti-TNFα Fc fusion protein containing additional glycosylation sites (see, for example, Courtois et al.).
[0156] In certain embodiments, the anti-TNFα transgene comprises a nucleotide sequence encoding the TNFR2:Fc fusion protein etanercept (having the amino acid sequence of SEQ ID NO: 10 or 11; see Table 6 and Figure 2A). The nucleotide sequence can be codon-optimized for expression in human cells. The nucleotide sequence may include, for example, the nucleotide sequences of SEQ ID NOs: 13-18 (encoding the etanercept transgene sequence shown in Table 7). The TNFR2:Fc fusion sequence has a signal or leader sequence at its N-terminus suitable for expression and secretion in human cells, particularly one or more ocular tissue cells. The signal sequence may have the amino acid sequence of MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62). Alternatively, the signal sequence may have an amino acid sequence selected from any one of the signal sequences shown in Table 2, corresponding to a protein secreted by one or more ocular tissue cells. Alternatively, the signal sequence may be suitable for expression in muscle or hepatocytes, such as those listed in Tables 3 and 4 below.
[0157] Soluble extracellular proteins of the TNFR2 type domain, and C H 2 and C H In addition to the Fc constant region containing the 3-domain sequence, the transgene contains heavy chain C HThe N-terminus of the two-domain sequence may include all or part of the hinge region. In certain embodiments, the Fc domain has an additional hinge region sequence at the N-terminus (e.g., SEQ ID NO: 3 with hinge), or has the amino acid sequence of SEQ ID NO: 4, which includes all or part of the amino acid sequence EPKSCDKTHTCPPCPAPELLGG (SEQ ID NO: 145), and in particular EPKSCDKTHL (SEQ ID NO: 146), EPKSCDKTHT (SEQ ID NO: 147), EPKSCDKTHTCPPCPA (SEQ ID NO: 148), EPKSCDKTHLCPPCPA (SEQ ID NO: 149), EPKSCDKTHTCPPCPAPELLGGPSVFL (SEQ ID NO: 150), or EPKSCDKTHLCPPCPAPELLGGPSVFL (SEQ ID NO: 151). The Fc domain of the anti-TNFα Fc fusion protein may have the amino acid sequence of SEQ ID NO: 3 or 4 (Table 6), or an IgG1 Fc domain, or a variant or variant thereof, as shown in Figure 4. The Fc domain may be manipulated for modified binding to one or more Fc receptors and / or effector functions, as disclosed in Section 5.2.8 below.
[0158] Etanercept expression can be directed by a constitutive promoter or a tissue-specific promoter. In certain embodiments, the transgene contains a CAG promoter (SEQ ID NO: 51), a CB promoter (SEQ ID NO: 159), a CB long promoter (SEQ ID NO: 161), a GRK1 promoter (SEQ ID NO: 54), or a Best1 / GRK promoter (SEQ ID NO: 161). Alternatively, the promoter may be a tissue-specific promoter (or a regulatory sequence containing promoter and enhancer elements) such as a GRK1 promoter (SEQ ID NO: 54 or 117), a mouse pyramidal arrestin (CAR) promoter (SEQ ID NO: 114-116), a human red opsin (RedO) promoter (SEQ ID NO: 112), or a Best1 / GRK promoter (SEQ ID NO: 161). See Figure 1 for a schematic diagram showing the genome structure. The transgene may contain elements provided in Table 1. Exemplary transgenes encoding etanercept The transgenes are provided in Table 7 and include CAG.etanercept (SEQ ID NO: 16) or mU1a.Vh4i.etanercept.scAAV (SEQ ID NO: 18). The ITR sequence is added to the 5' and 3' ends of the construct to generate a genome yielding CAG.etanercept (SEQ ID NO: 15) and U1a.Vh4i.etanercept.scAAV (SEQ ID NO: 17). In certain embodiments, the construct is a self-complementary construct. The transgene may be packaged in an AAV, particularly AAV2.7m8, AAV8, AAV3B, or AAVrh73.
[0159] In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein containing a soluble extracellular portion of a TNFR2-type domain, comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 2. In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein containing an Fc domain, comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 3. In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 10 or 11. In certain embodiments, the TNFR2:Fc fusion protein comprises the amino acid sequence of SEQ ID NO: 10 or 11, having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more amino acid substitutions, insertions, or deletions, and such substitutions, insertions, or deletions are produced.
[0160] In certain embodiments, the anti-TNFα transgene comprises a nucleotide sequence encoding the TNFR1:Fc fusion protein EYS606 (having the amino acid sequence of SEQ ID NO: 12; see Table 6 and Figure 2B). The nucleotide sequence can be codon-optimized for expression in human cells. The TNFR1:Fc fusion sequence has a signal or leader sequence at its N-terminus suitable for expression and secretion in human cells, particularly one or more cells forming the retina. The signal sequence may have the amino acid sequence of MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62). Alternatively, the signal sequence may have an amino acid sequence selected from any one of the signal sequences shown in Table 2, corresponding to a protein secreted by one or more ocular tissue cells. Alternatively, the signal sequence may be suitable for expression in muscle or hepatocytes, such as those listed in Tables 3 and 4 below.
[0161] Soluble extracellular proteins of the TNFR1 type domain, and C H 2 and C H In addition to the Fc constant region containing the 3-domain sequence, the transgene contains heavy chain C H The N-terminus of the two-domain sequence may include all or part of the thrombin cleavage site LVPRGS (SEQ ID NO: 8) and the hinge region. In certain embodiments, the Fc domain has the amino acid sequence of SEQ ID NO: 3, or has a hinge region sequence at the N-terminus that includes all or part of the amino acid sequence DKTHTCPPCPAPELLGG (SEQ ID NO: 21), and in particular DKTHTCPPCPA (SEQ ID NO: 154), DKTHLCPPCPA (SEQ ID NO: 155), DKTHTCPPCPAPELLGGPSVFL (SEQ ID NO: 152), or DKTHLCPPCPAPELLGGPSVFL (SEQ ID NO: 156). The Fc domain of the anti-TNFα Fc fusion protein may have the amino acid sequence of SEQ ID NO: 10 (Table 6). The Fc domain may be manipulated for modified binding to one or more Fc receptors and / or effector functions, as disclosed in Section 5.2.8 below.
[0162] EYS606 expression may be directed by a constitutive promoter or a tissue-specific promoter. In certain embodiments, the transgene contains a CAG promoter (SEQ ID NO: 51) or a GRK1 promoter (SEQ ID NO: 54). Alternatively, the promoter may be a tissue-specific promoter (or a regulatory sequence containing promoter and enhancer elements) such as the GRK1 promoter (SEQ ID NO: 54 or 117), the mouse pyramidal arrestin (CAR) promoter (SEQ ID NOs: 114-116), the human red opsin (RedO) promoter (SEQ ID NO: 112), or the Best1 / GRK promoter (SEQ ID NO: 161). The transgene may contain elements provided in Table 1. Exemplary transgenes encoding EYS606 may be generated using methods known in the art. The ITR sequence is appended to the 5' and 3' ends of the construct to generate the genome. The transgene may be packaged in an AAV, particularly AAV8, AAV3B, or AAVrh73.
[0163] In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein containing a soluble extracellular portion of a TNFR1-type domain, comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 1. In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein containing an Fc domain, comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 6. In certain embodiments, the transgene encodes an anti-TNFα Fc fusion protein comprising an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence shown in SEQ ID NO: 12. In certain embodiments, the TNFR1:Fc fusion protein comprises a soluble extracellular portion of a TNFR1-type domain containing the amino acid sequence of SEQ ID NO: 1, having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid substitutions, insertions, or deletions, wherein such substitutions, insertions, or deletions are produced. In certain embodiments, the TNFR1:Fc fusion protein comprises the amino acid sequence of SEQ ID NO: 12, which has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid substitutions, insertions, or deletions, and such substitutions, insertions, or deletions are created, for example, in the framework region.
[0164] Methods of gene therapy A method is provided for treating human subjects with non-infectious uveitis by administering a viral vector containing a transgene encoding an anti-TNFα fusion protein. The fusion protein may be etanercept or EYS606, or a biobetter or biosimilar thereof. In embodiments, the patient is diagnosed with non-infectious uveitis and / or has symptoms(s) associated with non-infectious uveitis. The recombinant vector used to deliver the transgene is described in Section 5.2. Such a vector should be tropic to human ocular tissue cells and may contain non-replicating rAAV, particularly AAV8 capsid, AAV3B capsid, or AAVr73 capsid. Alternatively, vectors carrying AAV2.7m8 or AAV9 capsids may be used for ocular indications. Recombinant vectors, such as those shown in Figure 1, can be administered in any manner such that the recombinant vector enters one or more ocular tissue cell types, for example, by introducing the recombinant vector into the eye. See Section 3 for further details on the treatment method.
[0165] A method is provided for treating human subjects with non-infectious uveitis by administering a viral vector containing a transgene encoding an anti-TNFα fusion protein. The fusion protein may be etanercept or EYS606. In embodiments, the patient is diagnosed with non-infectious uveitis and / or has symptoms associated with non-infectious uveitis. The recombinant vector used to deliver the transgene is described in Section 5.2, and exemplary transgenes are provided above. Such vectors should be tropic to human ocular tissue cells and may include those carrying non-replicating rAAV, particularly AAV3B, AAV8, or AAVrh73 capsids. Recombinant vectors, such as those shown in Figures 2A and 2B, can be administered in any manner to allow the recombinant vector to enter the ocular tissue. In certain embodiments, the transgenes are SEQ ID NOs. 13-18 in the AAV8 vector (see Table 7).
[0166] The subjects to whom such gene therapy is administered may be those who respond to anti-TNFα therapy. In certain embodiments, the method encompasses treating patients who have been diagnosed with non-infectious uveitis or who have one or more associated symptoms and who have been identified as responsive to treatment with anti-TNFα antibodies, anti-TNFα Fc fusion proteins, or who are considered good candidates for therapy with anti-TNFα antibodies or anti-TNFα Fc fusion proteins. In certain embodiments, the patient has been previously treated with etanercept, adalimumab, infliximab, or golimumab and has been found to respond to etanercept, adalimumab, infliximab, or golimumab. In other embodiments, the patient has been previously treated with anti-TNFα antibodies or fusion proteins such as etanercept, certolizumab, or other anti-TNF-α agents. To determine responsiveness, an anti-TNFα transgene product (e.g., produced in cell cultures, bioreactors, etc.) may be directly administered to the subject.
[0167] Human post-translational modified anti-TNFα fusion protein The production of HuPTM anti-TNFα fusion protein should result in a “bio-better” molecule for the treatment of non-infectious uveitis achieved via gene therapy, for example, by administering a viral vector or other DNA expression construct encoding the anti-TNFα HuPTM anti-TNFα fusion protein subretinal, intravitreous, intranasal, anterior chamber, suprachoroidal, or systemically to a human subject (patient) diagnosed with or having one or more symptoms of non-infectious uveitis, by creating a permanent depot in one or more ocular tissues (or cell types) that continuously supply a fully human post-translationally modified, for example, transduced ocular tissue cells, using a viral vector or other DNA expression construct encoding the anti-TNFα HuPTM anti-TNFα fusion protein.
[0168] In certain embodiments, the HuPTM anti-TNFα fusion protein has a soluble extracellular portion of a TNFR2 domain fused to an Fc domain having the amino acid sequence of etanercept shown in Figure 2A (aspartic acid (N) glycosylation site, non-consensus aspartic acid (N) glycosylation site; as shown in the legend), and has glycosylation, particularly 2,6-sialylation, at one or more of the amino acid positions shown in Figure 2A, and includes N149 or N171 of the TNFR2 domain (SEQ ID NO: 2) and / or N317 of the Fc domain (SEQ ID NO: 3), and / or O-linked glycosylation sites at one or more of the amino acid positions T8, T184, S199, and / or T200 of the TNFR2 domain (SEQ ID NO: 2), and / or T245 (SEQ ID NO: 11) of the hinge region. In other embodiments, the HuPTM anti-TNFα fusion protein does not contain any detectable NeuGc moiety and / or any detectable alpha-Gal moiety.
[0169] In certain embodiments, the HuPTM anti-TNFα fusion protein has a soluble extracellular portion of the TNFR1 domain fused to an Fc domain having the amino acid sequence ESY606 shown in Figure 2B (aspartic acid (N) glycosylation site, non-consensus aspartic acid (N) glycosylation site; as shown in the legend), and has glycosylation, particularly 2,6-sialylation, at one or more of the amino acid positions shown in Figure 2B, and includes N54, N94 or N145 of the TNFR1 domain (SEQ ID NO: 1) and / or N294 or N358 of the Fc domain (SEQ ID NO: 12) and / or O-linked glycosylation sites at one or more of the amino acid positions T8, T184, S199, T200 of the TNFR2 domain (SEQ ID NO: 1) and / or T245 of the hinge region (SEQ ID NO: 12). In other embodiments, the HuPTM anti-TNFα fusion protein does not contain any detectable NeuGc moiety and / or any detectable alpha-Gal moiety.
[0170] In certain embodiments, the HuPTM anti-TNFα Fc fusion protein is therapeutically effective and is at least 0.5%, 1%, or 2% glycosylated and / or sulfated, and may be at least 5%, 10%, or even 50% or 100% glycosylated and / or sulfated. The goal of the gene therapy treatment provided herein is to slow, halt, or alleviate the progression of one or more symptoms of non-infectious uveitis, such as reducing the level of pain, ocular redness, photophobia, and / or other patient discomfort. Efficacy may be monitored by measuring pain reduction, ocular redness, and / or photophobia, and / or visual improvement.
[0171] The combination of delivery of HuPTM anti-TNFα Fc fusion protein to the eye in conjunction with the delivery of other available therapies is encompassed by the methods provided herein. Additional therapies may be administered before, concurrently with, or after gene therapy. Available therapies for subjects with non-infectious uveitis that can be combined with the gene therapy provided herein include, but are not limited to, azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, cyclophosphamide, corticosteroids (topical and / or systemic), and others, as well as administration with anti-TNFα agents including, but not limited to, etanercept, EYS606, adalimumab, infliximab, or golimumab. [Table 7-1] [Table 7-2] [Table 7-3] [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5] [Table 8-6] [Table 8-7] [Table 8-8] [Table 8-9]
[0172] 5.6 Dosage administration of anti-TNFα Fc fusion protein Any therapeutically effective dose of such recombinant vector should be administered in any manner that allows the recombinant vector to enter ocular tissue cells (e.g., retinal cells), for example, by introducing the recombinant vector into the bloodstream. Alternatively, the vector may be administered directly to the eye, for example, via subretinal, intravitreous, anterior chamber, or suprachoroidal injection. In certain embodiments, the vector is administered subretinal, intravitreous, anterior chamber, suprachoroidal, subcutaneous, intramuscular, or intravenously. Subretinal, intravitreous, anterior chamber, or choroidal administration should result in the expression of the soluble transgene product in one or more of the following retinal cell types: human photoreceptor cells (cone cells, rod cells); horizontal cells; bipolar cells; amarcline cells; retinal ganglion cells (midget cells, parasol cells, bilaminated cells, giant retinal ganglion cells, photosensitive ganglion cells, and Müller glia); as well as retinal pigment epithelial cells or other ocular tissue cells: corneal cells, iris cells, ciliary cells, Schlemm's canal cells, trabecular meshwork cells, RPE-colloid tissue cells, or optic nerve cells.
[0173] The expression of the transgene product results in the delivery and maintenance of the transgene product in one or more ocular tissues or ocular tissue cell types, such as retinal cells. A suitable pharmaceutical composition for administration comprises a suspension of a recombinant vector containing a transgene encoding an anti-TNFα Fc fusion protein in a formulation buffer containing a physiologically compatible aqueous buffer. The formulation buffer may contain one or more of the following: polysaccharides, surfactants, polymers, or oils.
[0174] Alternatively, a recombinant vector encoding an anti-TNFα Fc fusion is delivered to the liver to express and secrete the anti-TNFα Fc fusion into the circulatory system. In certain embodiments, the dose and route of administration of a vector containing a transgene encoding etanercept Fc fusion protein should result in the expression of etanercept Fc fusion protein that achieves and maintains intravitreous concentrations of etanercept fusion protein at levels equivalent to those achieved by monthly injections of etanercept (Amgen) at a dose of 40 mg.
[0175] 5.7 Monitoring of effectiveness The compositions and methods described herein may be evaluated for efficacy using any method for evaluating efficacy in the treatment, prevention, or remission of NIU. Evaluation may be determined in animal models or human subjects. Efficacy for visual impairment may be measured by evaluating the best corrected visual acuity (BCVA), e.g., the increase in the number of letters or lines; efficacy may be evaluated as an increase in two or more ETDRS lines or logMAR, a reduction in inflammatory activity in the anterior and posterior chambers according to the SUN classification, and / or a reduction in the grade of vitreous opacity. Physical changes to the eye may be measured by optical coherence tomography using methods known in the art.
[0176] The compositions and methods described herein may be evaluated for efficacy using any method for evaluating efficacy in the treatment, prevention, or remission of NIU. Evaluation may be determined in animal models or human subjects. Efficacy for visual impairment may be measured by evaluating the best corrected visual acuity (BCVA), e.g., the increase in the number of letters or lines; efficacy may be evaluated as an increase in two or more ETDRS lines or logMAR, a reduction in inflammatory activity in the anterior and posterior chambers according to the SUN classification, and / or a reduction in the grade of vitreous opacity. Physical changes to the eye may be measured by optical coherence tomography using methods known in the art. Efficacy can be monitored by determining the flare and / or recurrence rate, anterior chamber cells, vitreous cells, and vitreous opacity grade (e.g., grade ≤0.5+), and / or active retinal or choroidal (inflammatory) lesions (see, e.g., Kim J. Set al., Int Ophthalmol Clin. 2015 Summer;55(3):79-110 or Rosenbaum J. Set al. Volume 49, Issue 3, December 2019, Pages 438-445 (the whole of which is incorporated herein by reference)).
[0177] Endpoints include, but are not limited to, the following: mean change in vitreous opacity grade in study eyes from baseline to 12, 16, 20, 24, or 28 weeks, or at rescue (if earlier); percentage of responders in study eyes without relapses of active intermediate, posterior, or total uveitis at 12, 16, 20, 24, or 28 weeks; mean change in best-corrected visual acuity from baseline to 12, 16, 20, 24, or 28 weeks; change from baseline in quality of life / patient-reported outcome assessments; mean change in vitreous opacity grade and anterior ventricular cell grade from baseline to 12, 16, 20, 24, or 28 weeks; or change in immunosuppressive drug score from baseline to 12, 16, 20, 24, or 28 weeks. [Examples]
[0178] 6. Examples 6.1 Example 1: Etanercept cDNA-based vector An etanercept cDNA-based vector was constructed containing a transgene containing a nucleotide sequence encoding TNFR:Fc fusion etanercept (the amino acid sequence being SEQ ID NO: 10 or 11). The nucleotide sequence is the nucleotide sequence of SEQ ID NO: 13 or 14. The transgene also contains a nucleotide sequence encoding a signal peptide, e.g., MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62). See Figure 2A for the amino acid sequence of the transgene product. The vector may further contain constitutive promoters such as CAG and mU1a, alternative promoters such as EF1a or CB7 or CB (SEQ ID NO: 159) or CB long (SEQ ID NO: 160) promoters, or tissue-specific promoters such as eye tissue-specific promoters, particularly the GRK1 promoter (SEQ ID NO: 54) or Best1 / GRK promoter (SEQ ID NO: 161), or inductive promoters such as hypoxia-inducible promoters.
[0179] 6.2 Example 2: EYS060 cDNA-based vector Construct an EYS060 cDNA-based vector containing a transgene comprising a nucleotide sequence encoding TNFR:Fc fusion EYS060 (the amino acid sequence of SEQ ID NO: 12). The transgene also contains a nucleotide sequence encoding a signal peptide, e.g., MYRMQLLLLIALSLALVTNS (SEQ ID NO: 62). See Figure 2B for the amino acid sequence of the transgene product. The vector may further contain constitutive promoters such as CAG or mU1a, alternative promoters such as EF1a or CB7 or CB (SEQ ID NO: 159) or CB long (SEQ ID NO: 160) promoters, or tissue-specific promoters such as eye tissue-specific promoters, particularly GRK1 promoter (SEQ ID NO: 54), Best1 / GRK promoter (SEQ ID NO: 161), or inductive promoters such as hypoxia-inducible promoters.
[0180] 6.3 Example 3: Conjugation of TNFα to vectorized adalimumab IgG and Fab and vectorized etanercept across model species A. Vectorized adalimumab candidates isolated from model species including human, mouse, and rat were tested for their binding ability to TNFα. Following cis-plasmid transfection of 293T cells, vectorized antibodies were expressed and secreted into the cell supernatant. The cell supernatant was tested in ELISA, and plates were coated with recombinant TNFα derived from the aforementioned species (Figure 5A). Adalimumab IgG effectively bound to human and mouse-derived TNFα. Fab showed a similar binding profile to human TNFα as IgG. However, Fab showed poor binding to mouse TNFα compared to adalimumab IgG. Both IgG and Fab showed significantly reduced binding to rat TNFα.
[0181] B. Vectorized etanercept was assayed in the same manner for binding to human, mouse, and rat TNFα. Etanercept bound to all human, mouse, and rat-derived TNFα, and bound to rat TNFα better than adalimumab. See Figure 5B.
[0182] 6.4 Example 4: AAV-Mediated Ocular Gene Therapy for Non-Infectious Posterior Uveitis Non-infectious posterior uveitis is a form of eye inflammation that affects the retina and choroid of the eye and can lead to blindness. It afflicts approximately 38,000 Americans each year. Patients are usually treated with systemic steroids or corticosteroid therapy, which poses a high risk of systemic complications. In 2016, Humira (adalimumab), a human monoclonal antibody targeting tumor necrosis factor alpha (TNFα), was approved by the FDA and became the only systemic non-corticosteroid agent for the treatment of non-infectious uveitis (NIU), and has been widely used since then. In this study, vectorized anti-TNFα Fc fusion proteins containing CAG.etanercept or mU1a.Vh4i.etanercept.scAAV, or vectorized EYS606, as well as AAV8.CAG.GFP, are evaluated for the expression of AAV-mediated anti-TNFα Fc fusion proteins in mouse eye tissues via local administration. AAV8 NUL functions as a control vector. An efficacy test in the murine EAU model is also conducted to investigate the therapeutic potential of AAV-mediated anti-TNFα therapy for NIU.
[0183] The vectorized etanercept and EYS606 sequences are constructed and tested in vitro. The transduction efficiency and cell type specificity in wild-type mice are further evaluated. Young adult C57BL / 6 and B10.RIII mice (8 - 10 weeks old) are used in this study. Vectors containing CAG.etanercept (SEQ ID NO: 15 or 16 (with or without adjacent ITRs)), or mU1a.Vh4i.etanercept.scAAV (SEQ ID NO: 17 or 18 (with or without adjacent ITR sequences)), or vectorized EYS606, as well as AAV8.CAG.GFP and AAV8.NUL, are administered at different doses (1×10 7 、1×10 8 、及び1×10 9The drug is delivered to mouse eyes via subretinal injection (SR) in 1 μl of formulation buffer (vg / eye). Fundus and OCT imaging are performed 1, 2, and 4 weeks after SR injection. Eye samples are collected 5 weeks post-administration. The level of antibody or fusion protein expression in eye tissue is quantified by ELISA. Cell type specificity is determined by immunofluorescence staining with various retinal cell markers. Test vectors are selected for efficacy studies. Different routes of administration (ROAs), including choroidal, anterior chamber, and intravitreous injections, are also explored. Preferred ROAs are used for efficacy studies.
[0184] Efficacy studies are conducted by inducing experimental autoimmune uveitis (EAU) in B10.RIII mice by immunization with human IRBP peptide. A T cell-mediated ocular autoimmune response occurs in this model, peaking approximately 11–18 days post-induction. The test vector is administered to the mouse eye via a preferred ROA two weeks prior to or one week after EAU induction. The contralateral eye is delivered with the AAV.NUL vector and serves as a control. Fundus and OCT imaging, electroretinography (ERG), and optokinetic nystagmus (OKN) are examined at 10, 17, and 30 days post-EAU induction to monitor disease progression. Ocular tissue or the entire eyeball is collected five weeks post-EAU induction. The level of fusion protein expression in ocular tissue is detected and quantified by ELISA. Changes in retinal structure and neuronal survival are assessed by histology and immunofluorescence staining.
[0185] 6.5 Example 5: In vivo study This study evaluates in vivo AAV-mediated antibody expression in mouse eye tissue after local administration (subretinal (SR), Table 8) of full-length and Fab adalimumab antibodies in adeno-associated virus (AAV) vectors (AAV8.CAG.adalimumab.IgG (NIU001) and AAV8.CAG.adalimumab.Fab (NIU002)), as well as etanercept Fc fusion protein (AAV8.CAG.etanercept). [Table 9]
[0186] The vectorized adalimumab and etanercept sequences have been constructed and tested in vitro. In this study, young adult B10.RIII mice (6 - 8 weeks old) are used. Vectors containing AAV8.CAG.adalimumab.IgG, AAV8.CAG.adalimumab.Fab, AAV8.CAG.etanercept, and vehicle are delivered to the eyes of mice via subretinal (SR) injection at two different doses (1×10 8 and 1×10 9 vg / eye) in 1 μl of formulation buffer (Table 8).
[0187] Fundus and OCT imaging were performed 2 and 4 weeks after SR injection. Eye samples were collected 4 weeks after administration. The levels of antibody or fusion protein expression in eye tissues were quantified by ELISA. Cell type specificity was determined by immunofluorescent staining using various retinal cell markers. Changes in retinal structure and neuron survival were evaluated by histology and immunofluorescent staining at 2 and 4 weeks after administration.
[0188] 6.6 Example 6: Evaluation of Vector - Expressed Etanercept Binding Kinetics Evaluate the expression and purification of vectorized etanercept from AAV produced from cisplasmid. Compare the binding kinetics of the purified vectorized etanercept to TNFα proteins of various species with commercially available etanercept in various ligand - binding assays.
[0189] Binding Affinity Using Biacore (trademark) (Surface Plasmon Resonance (SPR)) Assay: Studies are conducted to measure the binding affinity of different TNF-alpha (TNFα) molecules to purified TNFR fusion proteins using a Biacore T200. First, the binding affinity of TNFα to the pAAV.CAG.etanercept-producing fusion protein is compared to the binding of TNFα to commercially available etanercept. Second, the binding affinities of TNFα from different species are tested to determine the suitability of various species of TNFα proteins for later animal model studies. The Biacore assay is performed at 25 °C using HBS-EP+ as the running buffer. Diluted fusion proteins are captured on the sensor chip by the Fc capture method (capture time of 15 - 20 minutes). TNFα proteins from different species (human, macaque, pig, mouse, dog, rabbit, and rat) are individually tested as analytes, followed by injection of the running buffer during the dissociation phase. The dissociation rate is calculated, [Koff = Kd = protein dissociation rate, Kon = Ka = protein association rate, K¬D = Koff / Kon], and smaller (lower) KD values indicate a higher affinity of the TNFR fusion protein for its target.
Table 10
[0190] The binding affinities (KD) of vectorized etanercepts of different species of TNFα to commercially available etanercept are ranked according to their KD values.
[0191] 6.7 Example 7: Measurement of TNF Fusion Protein Effector Function The effector functions of vector-produced etanercept, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are evaluated by in vitro assays and compared to commercially available etanercept (ENBREL). Effector functions are induced via the Fc domain of the antibody and thus via fusion proteins containing an Fc domain such as etanercept.
[0192] Materials and Methods Target cells (CHO / DG44-tm TNFα; GenScript catalog number RD00746) are maintained at 37°C and 5% CO2 in the corresponding complete culture medium. Effector cells (peripheral blood mononuclear cells, PBMC; Saily Bio catalog number XFB-HP100B) are thawed at 37°C and maintained at 37°C and 5% CO2 in 1640 complete culture medium.
[0193] In the ADCC dose-response assay, CHO / DG44-tm TNFα and PBMCs can be used as target cells and effector cells, respectively. Etanercept (commercially available) and human IgG1 are used as positive and negative controls for CHO / DG44-tm TNFα, respectively, with an E / T (effector cell vs. target cell) ratio set at 25:1. Briefly, the steps of the method are as follows: CHO / DG44-tm TNFα (target cell) + sample + PBMC (Effector Cells) ↓ Target cell lysis%
[0194] Effector cells (PBMCs) are thawed and resuspended in assay buffer (CellTiter-Glo® detection kit (Promega, catalog no. G7573)). Target cells are also thawed and resuspended in ADCC assay buffer, then transferred to assay plates in suspension according to the plate map. Control and test samples in solution are similarly transferred to assay plates, and the assay plates are incubated at room temperature for 30 minutes. Effector cell density is adjusted according to the E / T ratio, and then the effector cell suspension is transferred to assay plates. The assay plates are then incubated in a cell incubator (37°C / 5% CO2) for 6 hours, removed, and the supernatant from the corresponding wells of the assay plate is transferred to another 96-well assay plate. The LDH mixture (LDH cytotoxicity detection kit, Roche catalog no. 11644793001) is transferred to the corresponding wells of the second 96-well assay plate, and the luminescence / absorbance is read using a PHERAStar® (BMG LABTECH) plate reader.
[0195] In CDC dose-response studies, CHO / DG44-tm TNFα can be used as the target cell. In 5% NHSC (normal human serum complement), etanercept and human IgG1 can be used as positive and negative controls for CHO / DG44-tm TNFα, respectively. Briefly, the steps of the CDC assay method are as follows: CHO / DG44-tm TNFα (target cell) + sample + NHSC ↓ Target cell lysis%
[0196] Target cells are collected by centrifugation and resuspended in assay buffer (CellTiter-Glo® detection kit (Promega, catalog no. G7573)). Samples and controls are prepared in solution with CDC assay buffer. Target cell density is adjusted, and then the cell suspension is transferred to an assay plate. Controls and test samples in working solution are also transferred to the assay plate, and then the assay plate is incubated at room temperature for 30 minutes, and normal human serum complement (NHSC) working solution (Quidel, catalog no. A113) is added to the assay plate. The assay plate is incubated in a cell incubator (37°C / 5% CO2) for 4 hours, removed, and CellTiter-Glo® working solution is added to the corresponding wells, and the plate is incubated at room temperature for approximately 10-30 minutes. Luminescence data is read on a PHERAStar® FSX (BMG LABTECH) plate reader to determine the number of viable cells. Raw data from ADCC and CDC studies are exported from the PHERAStar® FSX system and saved to Microsoft Office Excel. Analysis is performed using GraphPad Prism 6 software. ADCC target cell lysis % formula = 100 * (OD sample - OD tumor cells + effector cells) / (OD maximum release - OD minimum release). CDC target cell lysis % formula = 100 * (1-(RLU sample-RLUNHSC) / (RLU cells+NHSC-RLUNHSC)). The relative EC50 value is obtained using the following four-parameter function, which characterizes a sigmoid curve where the target cell lysis % is relative to the concentration of the test sample: Y = bottom + (top - bottom) / (1 + 10^((LogEC50-X)) * HillSlope)) = Percentage of target cell lysis, and X = Concentration.
[0197] With an E / T ratio of 25:1, CHO / DG44-tm TNFα cells can be used as target cells in ADCC dose-response studies. Calculate the dose-response and best fit (e.g., EC50) for positive control (commercial etanercept), sample, and negative control (human IgG1).
[0198] In 5% NHSCs, CHO / DG44-tm TNFα cells are used as target cells in CDC dose-response studies. Dose-response and best fit values (e.g., EC50) are calculated for positive control (etanercept), sample, and negative control (human IgG1).
[0199] The ADCC and CDC activities of AAV-etanercept are compared with those of commercially available etanercept. Without being bound by any particular theory, differences may be observed due to post-translational modifications such as glycosylation, which are expected to differ depending on the manufacturing cell culture of commercially available etanercept.
[0200] Equal portions While the present invention has been described in detail with reference to its specific embodiments, it will be understood that functionally equivalent modifications fall within the scope of the invention. Indeed, in addition to those shown and described herein, various modifications of the invention will be apparent to those skilled in the art from the foregoing description and the accompanying drawings. Such modifications are intended to fall within the scope of the accompanying claims. Those skilled in the art will be able to recognize or confirm many equivalents to the specific embodiments of the invention described herein by mere conventional experimentation. Such equivalents are intended to be encompassed by the following claims.
[0201] All publications, patents, and patent applications referenced herein are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application were specifically and individually indicated as being incorporated herein by reference in whole.
Claims
1. 1. A pharmaceutical composition for treating non-infectious uveitis in a human subject in need thereof, comprising: (a) a viral capsid having tropism for human ocular cells; (b) an adeno-associated virus (AAV) vector having an artificial genome comprising an expression cassette flanked by AAV internal tandem repeats (ITRs), the expression cassette comprising a transgene encoding an anti-TNFα Fc fusion protein operably linked to one or more regulatory sequences that control expression of the transgene in a human ocular cell; the AAV vector is formulated for subretinal, intravitreal, intranasal, intracameral, or suprachoroidal administration to the human subject; The pharmaceutical composition.
2. 2. The pharmaceutical composition of claim 1, wherein the anti-TNFα Fc fusion protein comprises a soluble extracellular portion of the human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently linked via a peptide bond to a polypeptide comprising the Fc domain of an immunoglobulin heavy chain.
3. The virus capsid is AAV serotype 1 (AAV1), serotype AAV2.7m8 (AAV2.7m8), serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 6 (AAV6), serotype 7 (AAV7), Serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rh10 (AAVrh10), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.
2. The pharmaceutical composition of claim 1, wherein the amino acid sequence of AAV is at least 95% identical to the amino acid sequence of AAVhu.37 (AAVhu.37), serotype rh73 (AAVrh73), or serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26).
4. 4. The pharmaceutical composition of claim 3, wherein the AAV capsid is AAV8, AAV3B, AAV2.7m8, or AAVrh73.
5. 2. The pharmaceutical composition of claim 1, wherein the human ocular cell is a corneal cell, an iris cell, a ciliary body cell, a Schlemm's canal cell, a trabecular meshwork cell, a retinal cell, an RPE-choroid cell, or an optic nerve cell.
6. 2. The pharmaceutical composition of claim 1, wherein the one or more regulatory sequences comprise a regulatory sequence of a CAG / CB7 promoter (SEQ ID NO:73), a CAG promoter (SEQ ID NO:74), an mU1a promoter (SEQ ID NO:75), an EF-1α promoter (SEQ ID NO:76), a human UbC promoter (SEQ ID NO:211), a CB promoter (SEQ ID NO:273 or 274), a human red opsin (RedO) promoter (SEQ ID NO:212), a human rhodopsin (Rho) promoter (SEQ ID NO:213), a mouse cone arrestin (CAR) promoter (SEQ ID NO:214, 215 or 216), a human rhodopsin kinase (GRK1) promoter (SEQ ID NO:77 or 217), a human bestrophin 1 (BEST1) promoter (SEQ ID NO:218, 219, 220 or 221), or a Best1 / GRK1 tandem promoter (SEQ ID NO:275).
7. 6. The pharmaceutical composition of claim 5, wherein the one or more regulatory sequences comprise a human rhodopsin kinase (GRK1) promoter (SEQ ID NO:54 or 117), a mouse cone arrestin (CAR) promoter (SEQ ID NOs:114-116), a human red opsin (RedO) promoter (SEQ ID NO:112), a CB promoter (SEQ ID NO:159), a CB long promoter (SEQ ID NO:160), or a Best1 / GRK promoter (SEQ ID NO:161).
8. The pharmaceutical composition of claim 1 , wherein the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that directs secretion and post-translational modification in the human ocular cell.
9. The signal sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO:62), MNFLLSWVHWSLALLLYLHHAKWSQA (SEQ ID NO: 64), MERAAPSRRVPLPLLLLLGGLALLAAGVDA (SEQ ID NO: 65), MAPLRPLILALLAWVALA (SEQ ID NO: 66), MRLLAKIICLMLWAICVA (SEQ ID NO: 67), MRLLAFLSLLALVLQETGT (SEQ ID NO: 68), MKWVTFISLLFLFSSAYS (SEQ ID NO: 69), MAFLWLLSCWALLGTTFG (SEQ ID NO: 70), MYRMQLLSCIALILALVTNS (SEQ ID NO:71), or MNLLLILTFVAAAVA (SEQ ID NO: 72) 9. The pharmaceutical composition of claim 8, wherein
10. 2. The pharmaceutical composition of claim 1, wherein the transgene has the following structure from N-terminus to C-terminus: signal sequence-soluble TNFR extracellular domain-hinge region-Fc domain-polyA.
11. The composition of claim 10, wherein the transgene further comprises a thrombin cleavage site of SEQ ID NO:8 at the C-terminus of the soluble TNFR extracellular domain.
12. The pharmaceutical composition of claim 1 , wherein the anti-TNFα Fc fusion protein is expressed as a dimeric fusion protein.
13. The pharmaceutical composition of claim 1 , wherein the anti-TNFα Fc fusion protein is etanercept or EYS606.
14. The pharmaceutical composition of claim 1, wherein the transgene comprises a nucleotide sequence of SEQ ID NO:13-18.
15. The pharmaceutical composition of claim 1 , wherein the anti-TNFα Fc fusion protein has the amino acid sequence of SEQ ID NO: 10, 11 or 12.
16. The pharmaceutical composition of claim 1, wherein the Fc domain is an IgG1-Fc domain.
17. The pharmaceutical composition of claim 1 , wherein the artificial genome is self-complementary.
18. 2. The pharmaceutical composition of claim 1, wherein the artificial genome is the construct CAG.etanercept (SEQ ID NO: 15) or mU1a.Vh4i.etanercept.scAAV (SEQ ID NO: 17).
19. 1. A composition comprising an adeno-associated virus (AAV) vector, a. AAV serotype 1 (AAV1), serotype AAV2.7m8 (AAV2.7m8), serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AA) V8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rh10 (AAVrh10), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu. a viral AAV capsid that is at least 95% identical to the amino acid sequence of AAVhu.37, serotype rh73 (AAVrh73), or serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26); b. an artificial genome comprising an expression cassette flanked by AAV inverted terminal repeats (ITRs), the expression cassette comprising a human soluble TNFα receptor type I (TNFR1) or type II (TNFR2) extracellular domain covalently linked via a peptide bond to a polypeptide comprising an Fc domain of an immunoglobulin heavy chain, the artificial genome comprising a transgene encoding an anti-TNF-α Fc fusion protein operably linked to one or more regulatory sequences that facilitate expression of the transgene in human ocular cells; the transgene encodes a signal sequence at the N-terminus of the anti-TNFα Fc fusion protein that directs secretion and post-translational modification of the anti-TNFα Fc fusion in human ocular cells; The composition.
20. 20. The composition of claim 19, wherein the transgene further comprises a thrombin cleavage site of SEQ ID NO:8 at the C-terminus of the soluble human TNFR extracellular domain.
21. The composition of claim 19 , wherein the anti-TNFα Fc fusion protein has the amino acid sequence of SEQ ID NO: 10, 11 or 12.
22. 20. The composition of claim 19, wherein the anti-TNFα Fc fusion protein is etanercept or EYS606.
23. 20. The composition of claim 19, wherein the human ocular cell is a corneal cell, an iris cell, a ciliary body cell, a Schlemm's canal cell, a trabecular meshwork cell, a retinal cell, an RPE-choroid cell, or an optic nerve cell.
24. 20. The composition of claim 19, wherein the transgene comprises the nucleotide sequence of SEQ ID NO: 13 or 14.
25. The signal sequence is MYRMQLLLLIALSLALVTNS (SEQ ID NO:62), MNFLLSWVHWSLALLLYLHHAKWSQA (SEQ ID NO: 64), MERAAPSRRVPLPLLLLLGGLALLAAGVDA (SEQ ID NO: 65), MAPLRPLILALLAWVALA (SEQ ID NO: 66), MRLLAKIICLMLWAICVA (SEQ ID NO: 67), MRLLAFLSLLALVLQETGT (SEQ ID NO: 68), MKWVTFISLLFLFSSAYS (SEQ ID NO: 69), MAFLWLLSCWALLGTTFG (SEQ ID NO: 70), MYRMQLLSCIALILALVTNS (SEQ ID NO:71), or MNLLLILTFVAAAVA (SEQ ID NO: 72) 20. The composition of claim 19, wherein
26. 20. The composition of claim 19, wherein the artificial genome is self-complementary.
27. 20. The composition of claim 19, wherein the artificial genome is the construct CAG.etanercept (SEQ ID NO: 15 or 16) or mU1a.Vh4i.etanercept.scAAV (SEQ ID NO: 17 or 18).
28. 1. A method for producing a recombinant AAV comprising the steps of: (c) (i) an artificial genome comprising a cis expression cassette flanked by AAV ITRs, said cis expression cassette comprising a transgene encoding an anti-TNFα Fc fusion protein, said anti-TNFα Fc fusion protein comprising a soluble extracellular portion of human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently linked via a peptide bond to a polypeptide comprising an Fc domain of an immunoglobulin heavy chain, operably linked to one or more regulatory sequences that facilitate expression of said transgene in human ocular cells; (ii) a trans-expression cassette lacking AAV ITRs, said trans-expression cassette encoding AAV rep and AAV capsid proteins operably linked to expression control elements that drive expression of said AAV rep and AAV capsid proteins in a host cell in culture and provide said AAV rep and said AAV capsid proteins in trans, said capsid having ocular tissue tropism; (iii) culturing the host cells that contain adenovirus helper functions sufficient to allow replication and packaging of the artificial genome by the AAV capsid proteins; (d) recovering from the cell culture a recombinant AAV that encapsidates the artificial genome.
29. 29. The method of claim 28, wherein the human ocular cell is a corneal cell, an iris cell, a ciliary body cell, a Schlemm's canal cell, a trabecular meshwork cell, a retinal cell, an RPE-choroid cell, or an optic nerve cell.
30. The transgene encodes etanercept or EYS606, and the AAV capsid protein is selected from the group consisting of AAV serotype 1 (AAV1), serotype 2.7m8, serotype 3 (AAV3), serotype 3B (AAV3B), serotype 4 (AAV4), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9 (AAV9), serotype 9e (AAV9e), serotype rhlO (AAVrhlO), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu. 37 (AAVhu.37), serotype rh73 (AAVrh73), or serotype rh74 (AAVrh74), serotype hu51 (AAV.hu51), serotype hu21 (AAV.hu21), serotype hu12 (AAV.hu12), or serotype hu26 (AAV.hu26).
31. A host cell comprising: An artificial genome comprising a cis expression cassette flanked by AAV ITRs, said cis expression cassette comprising a transgene encoding an anti-TNFα fusion protein, said anti-TNFα Fc fusion protein comprising a soluble extracellular portion of human TNFα receptor type I (TNFR1) or type II (TNFR2) covalently linked via a peptide bond to a polypeptide comprising an Fc domain of an immunoglobulin heavy chain, operably linked to one or more regulatory sequences that facilitate expression of said transgene in human ocular cells. The host cell.
32. 32. The host cell of claim 31 , wherein the transgene encodes etanercept or EYS606.
